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Epidemiology of breast cancer
Of the more than 100 different malignancies that may develop in the human, carcinoma of the 
female breast is the most frequent occurring type of cancer in women. Moreover it is also the 
most frequent cause of cancer-related death in this group. Patients with a positive family history 
for breast cancer are at higher risk for developing breast cancer than the general population, and 
in 4-7% of the cases with breast cancer a Mendelian inheritance pattern can be found (33). During 
recent years in the Netherlands the incidence of breast cancer is increasing. According to the 
Dutch association of comprehensive cancer centres, in 1989 100 of every 100,000 women were 
diagnosed to have breast cancer, while in 1994 121 of every 100,000 women were diagnosed 
with breast cancer. This increase is mainly due to a rise in nonpalpable breast cancers diagnosed 
by a combination of increasing use of mammography, improvements in its technique, more 
accurate interpretation and the use of wire-directed breast biopsy. In contrast to the increase in 
incidence the mortality from breast cancer in women decreased slightly (63). Between 1989-1994 
in the Netherlands 39 in every 100,000 women died of breast cancer compared to 36.8 of every 
100,000 women in 1997. There is no evidence, based on currently available treatments that 
further decrease in mortality will occur as a result of therapy.
Prevention
Primary prevention of breast cancer by ingestion of products such as drugs or nutrients only 
proved useful in the case of tamoxifen (65). The value of these preventive regimens has not yet 
been established.
Secondary prevention by early detection however, is generally accepted and can achieve a 
reduction in mortality. Breast self-examination, clinical breast examination and mammography 
have been recommended as combined modalities for breast cancer screening. Breast self­
examination alone did not lead to any decrease of mortality in a randomised controlled trial in the 
United Kingdom, even if women were taught breast self-examination (14,77). A recent study 
among 266,064 women in China had similar findings (69). On the other hand breast self­
examination can have a role in early detection of breast abnormalities, reducing the period 
between the first detectable symptom and therapy.
Although it is important to teach clinical breast examination to medical residents (25), in a 
clinical setting the value of clinical assessment was low compared to mammography (66). 
Shapiro et al. were the first to publish results on long-term follow up of women with clinical 
investigation and mammography. They observed 52 deaths due to breast cancer in a control 
group, as compared to 31 deaths of breast cancer in a study group of 31,000 women, aged 40 to 
64 years who participated in a periodic breast cancer screening program (61). In the Netherlands, 
the Nijmegen region started a screening program in 1971 to evaluate the effectiveness of breast 
cancer screening using mammography. Screening trials in Nijmegen and Utrecht (DOM-project), 
both using mammography for screening, made clear that decreases in mortality from breast 
cancer could be expected in a nation-wide screening program (24,42). The effect of a single 
screening round on reduction in breast cancer related mortality was found to be 46% in the DOM 
project, after a period of 17 years of biannual breast cancer screening. This percentage rose to 
68% if women had more than four investigations (55). In the Netherlands a nation-wide program
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of screening for breast cancer was started in 1990, providing a biannual screen mammography to 
women aged 50 to 69 years. This program has been implemented successfully with an attendance 
rate of 78.5% between 1990 and 1999 (24,77). The data on this screening project suggest a 
significant reduction of breast cancer mortality in the latest years: 1997, 1998 and 1999 (78). 
During the first five years of the screening program a reduction in breast cancer related mortality 
could not be established.
Although several studies have reported a reduction in the mortality in the screened population, 
the effect of breast cancer screening on breast cancer mortality is still under extensive discussion 
(1,3,4,26,27,39,40,67,68,72). Benjamin analysed seven randomised breast cancer-screening trials, 
commonly cited as having produced evidence for reduced breast cancer mortality. He found 
flaws in all trials and concluded that claims on the reduction of breast cancer mortality after 
mammographic screening are therefore unproven. Roberts evaluated the Edinburgh trial of 
screening for breast cancer and found that after a follow up of seven years the mortality was not 
significantly reduced in the screened group. Unfortunately their attendance rate was low and they 
included women 45-49 years of age, so the results were diluted by non-attendance and poorer 
results in the younger age group (59). A meta-analysis, including the Swedish trials, the 
Edinburgh trial, the New York trial, and Danish trials, did not show a decrease in mortality after 
breast cancer screening, concluding that screening for breast cancer with mammography is 
unjustified (32). The Danish investigators Peter Gotzsche and Ole Olsen strongly suggest that 
several trials were biased. Moreover they stated that even if these trials were not biased, 
screening would still not be justified, because cardiac and pulmonary side effects of treatment 
increase the total number of deaths, while breast-cancer-related mortality decreased only slightly. 
Unfortunately in these trials patients aged 39-49 years were included. From the discussions 
mentioned above it may be evident that the gain in life expectancy, caused by a breast cancer 
screening program, is hard to measure.
Recently the policy for the Netherlands for the coming years was re-evaluated by a committee 
from the ‘Gezondheidsraad’ (Heath Council), because of the results published in the Lancet from 
the study by Gotzsche and Olsen. This council decided to continue breast cancer screening for the 
Netherlands because they do not share the criticism of the Danish investigators on the 
randomised controlled trials. They felt that the end points of the trials, breast cancer mortality, 
could not be changed for general mortality, like the Danish investigators stated. The members 
from the committee concluded that the expected decrease in breast cancer mortality could be less 
than expected in 1990, but they found no solid scientific grounds to stop the screening program. 
They suggest to further establish the value of breast cancer screening by investigating individual 
dead patients in relation to family background, screening history, treatment and other data, in 
order to establish the value of breast cancer screening (29).
Screening in younger women
Patients diagnosed with breast cancer before age 36 differ from older patients in numerous 
respects. They present more often with a palpable mass rather than a mammographic finding and 
their cancers are more advanced with features that are more aggressive. Despite aggressive 
treatment, most commonly with mastectomy and chemotherapy, local and distant failure rates are 
higher than for patients of 36 years and older (28).
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In the Netherlands the screening starts from the age of 50. Although several studies observe a 
beneficial effect of screening in woman below 50 years of age (4,8,22,36,77), screening in 
younger women is generally considered not to be beneficial (48). Several reasons are mentioned 
in the literature (20,21). Silverstein found that biopsies of nonpalpable lesions in the group of 
patients under age 50 were only half as likely to reveal cancer than biopsies of nonpalpable 
lesions in patients aged 50 and older (63). Kerlikowske showed that of 10.000 women aged 40-49 
screened by mammography, about 640 women will have an abnormal mammogram; of these, 
about 150 will undergo biopsies, and of these, about 30 will be diagnosed as having either 
invasive or in-situ disease (40).
False positive examinations are more likely to occur in the 40- to 49-year-old age group than in 
older age groups (19). Younger patients have dense mammary tissue, which makes screening by 
mammography more difficult. In the Stockholm mammographic screening trial a breakpoint for 
benefit seemed to be 50 years of age when 5-year age groups were analysed, but this tendency is 
uncertain because of the low statistical power in the analysis of the younger age groups (27).
The above data indicate that it is difficult to state at which age women should be included in a 
population-screening program. At the present time, however, it seems not worthwhile to perform 
breast cancer screening in women before 50 years of age.
In high risk cases screening can be performed according to schedules of surveillance or with the 
use of contrast enhanced Magnetic Resonance Imaging.
Screening in older women
In women over 70 years screening seems to be beneficial towards reducing mortality of breast 
cancer. In a prospective cohort study comparing a population with a screening program for breast 
cancer and a reference population without screening, the conclusion was that mammographic 
screening of women older than 65 can be expected to yield a 40% reduction in breast-cancer 
mortality after 10 years (16). A study by Van Dijck showed that mammographic screening was 
beneficial at least up to the age of 75 years, although elderly women show a lower attendance rate 
reducing the efficiency of screening (15,23). Moreover, elderly women with a low bone mineral 
density (BMD) have a lower risk of breast cancer and may therefore benefit less from continued 
screening. An analysis of live expectancy and cost-effectiveness of screening mammography in 
elderly women concluded that continuing mammography screening after age 69 years results in a 
small gain of live expectancy and is moderately cost-effective in those with high BMD but is 
more costly in those with low BMD (41). Recently the screening age in the Netherlands was 
increased to 75 years.
No studies have been performed in women above 75 years of age and there seems no indication 
to perform screening in this higher age group, taking into account the problems with poor 
attendance and possible poor health status of elderly women.
Interval between screening rounds
The interval between screening rounds has a considerable impact on the reduction of breast 
cancer mortality. When the interval is increasing, the protective effect of the screening decreases 
(55). The goal should be to optimise the benefit by using the most appropriate screening 
intervals. In general a screening interval of 2 years is advised. Evidence indicates, however, that
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in breast cancer in younger women the maximum time between the earliest possible detection at 
screening and clinical findings in the absence of screening is shorter than in older women (18). 
The detection of faster growing tumours requires a shorter interval between screening rounds 
(20). In a recent study by van Gils using screening intervals of two years a significant 
improvement of screening performance in women with radiographically dense breasts was 
measured in later years (1982-1994), in comparison with screening in the early screening years 
(1977-1982). However, if the lead-time of the tumour is greater than one year, there is little 
improvement in the detection of tumours in patients with dense breasts. The authors advocate 
shortening screening intervals, taking additional mammographic views or using advanced 
imaging techniques in women with dense breasts (30).
Diagnostic protocol
In the Netherlands high attendance rates together with low referral rates for suspicious lesions 
allowed for a sufficient detection of small breast cancers, while keeping the false positive rate 
low (24). The referral rate in the Netherlands is documented 1.0%, which is low in contrast to 
most national breast cancer screening programs in other countries where the referral rate is at 
least twice as high. As expected the referral rate in the first screening round is generally higher 
than in subsequent rounds e.g.: for the screening program in the Netherlands this percentage is 
1.36%.
In The Netherlands women with a suspect lesion observed during screening are initially referred 
to the general practitioner. Further diagnostic procedures are, however, performed by a surgeon 
generally working within a multidisciplinary team. The first step in further diagnostic work-up 
will be to repeat mammography in order to get better quality pictures in several directions. 
Sometimes the mass cannot be seen on a second mammography, in which case there will be no 
further therapy, if there is no palpable mass as well (63).
In case mammography shows dense breast tissue and reading is difficult, ultrasound may be 
helpful. In a study by Maestro routine supplemental ultrasound evaluation, however, does not 
appear to significantly contribute to the accuracy of the work-up (46). In case a breast lesion is 
confirmed by imaging the next step will be a biopsy of the lesion, which can be performed in 
several ways.
Needle biopsies
Although until now surgical biopsy is the “gold standard” for the diagnosis of non-palpable 
breast lesions, some physicians use Fine Needle Aspiration (FNA) biopsy or percutaneous large 
core breast biopsy in an attempt to diagnose non-palpable breast lesions. A main advantage of 
making a definite diagnosis by needle biopsy before surgery is the observation in several series 
that resection margins of excisional biopsies prove to be more radical after the diagnosis of the 
lesions was known by needle biopsy (2). For FNA O’Neil et al. reported a sensitivity of 97% and 
a specificity of 78%. In their study only 0.7% of specimens were inadequate for cytological 
diagnosis (51). The Radiology Diagnostic Oncology Group 5 Study, on the other hand, found a 
very high rate of insufficient samples in their multi-institutional trial of almost 33%, which lead 
to abandoning of FNA under stereotactic guidance (56). In contrast, using ultrasound guidance 
several series showed a high accuracy of FNA (50). From this conflicting data it can be
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concluded that the results of FNA are highly variable. The FNA technique can only be a 
substitute for core and open biopsy in those institutions, where the practitioner can achieve a high 
level of adequate specimens and a high rate of accuracy in the cytological interpretation.
A far more constant and high degree of accuracy can be achieved with ultrasound guided large- 
core needle biopsies (47). Large core breast biopsy is a cost-effective, reliable, and expedient 
alternative to surgical biopsy, which offers a histological diagnosis instead of cytology (54). 
Stereotactic large core needle biopsy is increasingly applied in nonpalpable breast disease. A 
multicenter study in the Netherlands indicated that a high sensitivity rate (97%) and specificity 
rate (99%) could be achieved after implementing guidelines for the management of different 
categories of needle biopsy diagnoses. (73). Ultrasound-directed core biopsy is an easier 
technology than stereotactic core biopsy and can be done at a lower cost. The increasing accuracy 
of these techniques has led to increased use in the surgical practice, in some cases already 
replacing the surgical excisional or incisional biopsy (11).
Recently biopsy techniques have even been used to treat patients with breast lesions. Complete 
removal of mammographic lesions has been demonstrated with the use of vacuum-assisted 
devices. Residual cancer, however, was identified in 11 of 15 lesions (73%) after re-excision in a 
study by Liberman et al. (45). Until now these techniques seems only experimental for the 
treatment of breast lesions.
Breast M RI
Contrast enhanced magnetic resonance imaging of the breast seems as sensitive and more specific 
in the hands of some investigators than the combined traditional triple assessment for the 
diagnosis of malignant breast lesions, using examination, mammography and cytology (17). 
Therefore breast Magnetic Resonance Imaging (MRI) is likely to find a role as an adjunct to 
standard triple assessment in selected groups of patients, thus avoiding unnecessary surgical 
biopsies. Kuhl et al. investigated 192 asymptomatic and 6 symptomatic women of a high-risk 
group with MRI and conventional techniques. They found a sensitivity of 100% using breast 
MRI, while the sensitivity of mammography and ultrasound combined was 44%. The positive 
predictive value of mammography was 30%, while the positive predictive value of breast MRI 
was 64% (44), thus reducing the number of unnecessary lumpectomies by half.
Breast MRI seems to be a very reliable method in detecting breast abnormalities, with a high 
sensitivity. However, it is still an expensive and time consuming investigation, with the need of 
an intravenous access for administering contrast. In the near future MRI may very well be used to 
screen women who have a high risk for developing breast cancer. At this moment trials are 
conducted that probably will show the value of breast MRI in breast cancer screening in women 
with a high risk of developing breast cancer (7,44).
Therapeutic protocol
Because of the screening programs, treatment of breast cancer has changed during recent years. 
Mammographic screening has led to dramatic decreases in the size of invasive cancers over the 
past two decades (6). Because of smaller tumours, a greater percentage of the women will be 
candidates for breast conserving therapy, thereby increasing the use of radiotherapy (43,76). 
Large studies gave the proof that treatment of breast cancer patients in stages I and II with breast
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conservation, resulted in survival rates equal to patients treated with modified radical mastectomy 
(75). Breast conservation is indeed possible in the vast majority of breast cancer patients (5). 
Guidelines for treatment and quality assurance in the surgical management of mammographically 
detected lesions have been developed by the European Breast Cancer Working Group and stand 
model for the treatment policy in The Netherlands (49). If the tumour is palpable, the patients can 
be treated in the same way as women outside the screening program and their treatment will not 
constitute specific problems. However, a great number of patients will be referred with 
radiological suspect nonpalpable lesions with or without microcalcifications (76). When in these 
patients a needle biopsy procedure has not led to a definite diagnosis a surgical biopsy should be 
taken which is restricted in volume in order not to harm patients with eventually benign disease. 
Since 1977 a preoperative needle localisation technique is used with a flexible self-retaining 
barbed guide wire (57,70). The suspicious lesion has to be in close proximity to the tip of the 
localization wire; otherwise large portions of tissue have to be excised with high percentages of 
tumour-positive resection marges. Ultrasonographically guided localization can be accurate as 
well and may help during surgical biopsy in cases where mammographic localization can’t be 
performed (58).
After placement of the guide wire the patient is operated. The biopsy is generally performed 
under general anaesthesia using either a transverse or semi-circumareolar incision. Some authors 
describe a technique under local anaesthesia (12). After excision of the mass, radiography of the 
specimen should be performed in order to confirm complete excision. If the suspected area is not 
in the removed specimen repeat resection can be carried out only when good directions can be 
made towards the localisation of the tumour. If no directions can be made, the operation is ended. 
In that case waiting for a full pathology report is mandatory. If no pathological tissue is included 
in the biopsy, waiting for around two months is recommendable, before performing another 
excision after radiographic wire localisation.
Because around 30% of the patients will have a benign breast lesion it is important not to take too 
large biopsies that result in a poor cosmetic outcome. Moreover large biopsies with tumour- 
positive margins make subsequent mastectomy necessary, in cases where breast-conserving 
therapy could have been possible. The use of ultrasound while performing an excisional biopsy 
may allow the surgeon to take more accurate biopsies. (31).
The operative procedure as described above is time-consuming and necessitates close co­
operation between surgeon, radiologist and pathologist (12). Unfortunately, when malignancy is 
demonstrated in the surgical biopsy, resection margins often turn out to be inadequate leading to 
a second operation in order to complete the operative treatment of the breast or to stage the 
axillary lymph nodes. This observation stresses the importance of pre-operative diagnosis by 
needle biopsy, which can prevent inadequate resection margins or the need of a second procedure 
for axillary lymph node staging.
False positive results
In the Netherlands 4.535.000 screen examinations took place between 1990-1999. A total of 
45.633 (1.0%) women were referred to a hospital. In these 45.633 women 30.234 breast biopsies 
were taken, of which 21.466 contained a breast cancer (77). These figures show that the 
screening protocol has a considerable false positive rate. A national review of community 
mammography facilities in the United States found that even 10% of all screening mammograms 
gave a false positive result (10). In a recent American study a ten-year retrospective analysis was
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performed among 2400 women, 40- to 69 years old, entering a breast-cancer-screening program. 
Over 10 years, one third of the women screened had abnormal test results requiring additional 
evaluation, even though no breast cancer was present. The estimated cumulative risk of having at 
least one biopsy as a result of a false positive test was 19% after 10 mammograms (19). The rate 
of false-positive mammograms will be highest in the group of women with dense breasts. This 
will lead more often to referral and taking of biopsies (74). The authors state, however, that these 
biopsies should not be referred to as unnecessary, because they are inherent to the diagnosis of 
early-stage cancer.
Because only a percentage of the patients will eventually be diagnosed as having breast cancer, a 
number of patients will be operated on for benign diseases of the breast. These women 
experience the same fears, operations and period of waiting as the patients that turn out to have 
breast cancer. Although they have a more favourable outcome, their problems should not be 
forgotten. To keep the number of false positives as low as possible, the screening team must work 
with optimal quality. Physicians should educate women about the risk of a false positive result of 
a screening test for breast cancer (19). In the Dutch screening program from 1990-1999 a 
sufficient detection of small breast cancers (4.7 per 1000) has been achieved with a low referral 
rate (1.0%), implicating that it is possible to keep the false-positive rate at an acceptable level 
(24).
Interval breast cancers
Interval breast cancers are breast cancers that are diagnosed in between two screening rounds, 
after a previous negative screening result. In the Netherlands a biannual screening program is 
conducted, so the number of interval cancers within 24 months after a screening round is an 
indicator of the screening quality. According to the 2001 rapport from the National Evaluation 
Team for Breast cancer screening the incidence of interval breast cancers in the Netherlands is 
0.99 in 1000 women-years. The incidence rises from 0.42 per 1000 women-years in the first half 
year after screening to 2.31 per 1000 women-years in the fifth half-year after screening. There are 
no large differences in the various regions. The detected number of interval breast cancers is most 
likely to be an under registration, because of difficulties with detecting people after they have left 
a region (77). Not all interval breast cancers can be seen as results of a previous false-negative 
screening; in some cases revision of the screening mammography does not indicate a tumour. 
These interval cancers are called ‘true’ interval breast cancers.
Improving the false negative rates of the screening protocol has been tried by ultrasound and 
other modalities, such as computer-assisted reading of mammograms (38). An automated system 
for the detection of circumscribed masses and stellate lesions was able to find a substantial 
proportion of cancers that were missed in a screening program. In a set of 75 mammograms with 
subtle circumscribed masses, stellate lesions, and architectural distortions that were not detected 
by two radiologists, 60% of cancers were detected by such an automated system (9). These 
techniques might be useful in the future, after further improvements have been made.
Minimal surgical approach for breast cancer
Owing to breast cancer screening more small tumours are found. The question rises whether it is 
possible to reduce morbidity of treatment by performing a less aggressive treatment-strategy?
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Some authors state that it might be possible in the future to treat cancer by local excision only, in 
a carefully selected patient group of patients (12). For instance: Joensuu et al found a 20-year 
survival-rate of 92% for T1a-b disease and a 75% survival-rate for T1c in a follow up period of 
20 years of 265 patients treated for breast cancer. They postulate that although well-differentiated 
pT1a-b tumours have an excellent long-term prognosis, a significant proportion of women with 
either moderately or poorly differentiated pT1a-b tumours or pT1c tumours ultimately die of the 
disease (36). This implicates that the follow up period has to be long and selection for local 
treatment has to be thorough. However, all their patients were treated with a modified radical 
mastectomy and an axillary lymph node dissection, and not with local treatment only.
Singletary reviewed recent clinical trials of adjuvant therapy for early breast cancer and made the 
observation that overall survival is not impacted by the extent of the surgery. Low rates of 
axillary relapse are observed in patients treated with mastectomy without axillary dissection 
combined with the availability of systemic therapy as a substitute for surgical control of the 
axilla, which means that patients can often be spared the morbidity of axillary node dissection 
(64). Other authors, however, showed, in a large trial with 1,708 premenopausal patients, the 
poor value of adjuvant chemotherapy in achieving local control after modified radical 
mastectomy. Of these patients 852 women received chemotherapy combined with radiotherapy of 
the chest wall and regional lymph nodes while 856 women received chemotherapy alone. The 
locoregional recurrence rate was 32% in the chemotherapy alone group and 9% in the combined 
group (p<0.001) after a median length of follow up of 114 months (52). The results from present 
randomized trials indicate that adjuvant systemic therapy does not sufficiently prevent local 
recurrence (53).
Also in non-invasive breast cancer the question rises whether a less aggressive treatment is 
possible. Recently new standards for diagnosis and treatment of ductal carcinoma in situ were 
published (71,74). In an EORTC trial of 1010 patients with ductal carcinoma in situ (DCIS) 84% 
of 500 evaluable patients had a 4-year local relapse-free survival after surgery alone, while 91% 
of 502 evaluable patients had a 4-year local relapse-free survival after the combination of surgery 
and radiotherapy (log rank p=0.005). Although this is a strong indicator for the use of a 
combination of surgery and radiotherapy in breast conserving treatment of DCIS, still 24 of 502 
patients developed an invasive recurrence within these four years after the combined treatment 
(37).
The Dutch guidelines for the diagnosis and treatment of breast cancer have recently been revised 
extensively and the previously mentioned results have been implemented in the guidelines (79). 
These guidelines also state that because of the complex procedures for diagnosis and treatment of 
the different types and stages of breast cancer the treatment of breast cancer patients should be 
performed in a multidisciplinary team. In the diagnostic process the radiologist, surgeon and 
pathologist should all be involved. In the therapeutic process the surgeon, plastic surgeon, 
radiotherapist, and medical oncologist should be involved. These disciplines should meet 
regularly and all patients should be treated according to agreed protocols (60).
Because more in situ tumours are detected and more often smaller cancers are found, the optimal 
treatment for tumours detected by breast cancer screening is debatable and randomised trials on 
their management need to be expedited (12,13,34). At this moment a less aggressive treatment 
seems not to be possible without a loss in recurrence-free survival.
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In the last 10 years a nationwide breast cancer-screening program has been introduced in the 
Netherlands. A recent meta-analysis of several trials revealed many doubts on the efficacy of 
such a screening program. At this moment discussions arise in scientific papers, screening 
organisations, patients organisations and even at a governmental level about whether or not to 
continue the screening. Although this is a most interesting discussion, the aim of this thesis is to 
evaluate the screening process from a different point of view. The objectives of the studies from 
this thesis are to demonstrate the several implications of the screening program on daily work in 
surgical practice and for several aspects of our work.
Screen detected breast cancer patients show a better survival than breast cancer patients who are 
detected outside the screening program. This is mainly explained by early detection of screen- 
detected tumours. It may, however, be possible that other factors than tumour size are responsible 
for better survival figures. Screen detected cancers may be less aggressive than non-screen 
detected cancers. One way to determine tumour aggressiveness is to measure the Mitotic Activity 
Index (MAI). In recent literature quantitative factors, such as the MAI, are good prognostic 
factors for patient survival. They discriminate very well less aggressive tumours from more 
aggressive ones.
The aim of the study described in chapter 3 was to investigate whether there is a difference in 
the MAI between screen and non-screen detected breast cancers, indicating an advantage from 
breast cancer screening, and to evaluate the prognostic value of the MAI for recurrence free 
survival, adjusting for other prognostic factors.
Tumours that are detected in between two mammographic screening rounds, after a previous 
negative screening result are called interval carcinomas. The fact that these interval carcinomas 
arise relatively shortly after a normal mammogram has led to speculations about an aggressive 
behaviour of these tumours. On the other hand several authors report that interval carcinomas do 
not have a worse prognosis compared to symptomatic carcinomas.
The Mitotic Activity Index (MAI) is a strong prognostic factor for disease free survival.
The study, descibed in chapter 4, was undertaken to find out if interval carcinomas have a MAI 
in between the screen detected and symptomatic carcinomas, or if they have a higher MAI, 
indicating a more aggressive biological behaviour.
Familiality is one of the risk factors associated with the development of breast cancer. Evidence 
exists that after introduction of a population screening for breast cancer, screened women with 
breast cancer who, in retrospect, turn out to have a family history of breast cancer are staged in 
the same stages as women with breast cancer, discovered under close surveillance because of a 
positive family history. Thus indicating no advantage of the knowledge that an increased risk 
exists.
We would like to know whether familiality in patients with a family history of breast cancer leads 
to a different MAI compared to patients without a family history of breast cancer, suggesting a 
different biological behaviour of these tumours. In chapter 5 the relationship between familiality 
and clinical presentation, MAI and survival are studied.
Breast cancer screening generally leads to detection of early stage breast cancers. A great part of 
the detected tumours are non-palpable and are only detected by mammography. The patients are 
preferably treated by lumpectomy or quadrantectomy followed by radiotherapy, instead of a
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modified radical mastectomy, as a breast saving procedure is considered to lead to similar results 
on survival and local recurrences.
The results of local excision followed by radiotherapy as to local control are significantly better 
when the surgical margins of the excised palpable or non-palpable tumour are clearly negative. A 
microscopic positive margin remains to be a significant risk factor for local recurrence in the 
conservatively treated patients.
The aim of the study from chapter 6 is to determine which factors may possibly contribute to 
tumour-positive margins, reexcision and residual tumour in patients who underwent a 
lumpectomy as the initial stage in the treatment of breast cancer.
In order to achieve a reduction in mortality from breast cancer, it is essential that there is a high 
attendance rate of women in the population who are offered breast cancer screening. A certain 
amount of compression of the breast is necessary to improve image quality, to separate 
overlapping structures, to reduce motion artefact, and to decrease the radiation dose. For most 
women, breast compression is an uncomfortable experience. Some women report severe pain and 
even consider not returning for a future screening round. There has been growing interest in the 
pain experience of women undergoing mammography in the news media, among patient groups 
and in nursing journals. Compared to the huge amount of breast cancer literature, relatively little 
has been written about pain during mammography in the medical journals. Because early 
detection proved to be important in reducing mortality due to breast cancer and women may not 
attend breast cancer screening because of pain, investigation of the experienced pain is desirable. 
This descriptive study in chapter 7 was designed to determine the prevalence and intensity of 
pain experienced by women undergoing screening mammography. The presence of possible 
associated factors was investigated. The degree of alleged pain as a deterrent for further screening 
mammography also was investigated.
Breast cancer is the most frequently occurring malignancy in women, with a lifetime risk of 10­
12%. During recent decades the incidence of breast cancer has increased in Western Europe and 
the United States, while the mortality even decreased. Part of the increase in incidence is due to 
breast cancer screening programmes. Mammographic screening for breast cancer makes it 
possible to detect breast cancer in a sub-clinical or non-palpable stage. In chapter 8 we present 
our results and experience with non-palpable breast cancer and evaluate whether on the basis of 
these results a less invasive treatment of non-palpable breast cancer could be appropriate.
In women with a suspect mammography during screening the malignancy rate varies between 5 
and 70%, depending on training and experience of the screening team. In a section of the referred 
women with an abnormal screening mammography in one single direction no lesion will be 
found on a bi-directional in-hospital mammography or with ultrasound, while another section of 
the women will undergo a biopsy for a benign lesion or a malignancy. On the other hand, small 
malignant tumours may be missed during screening due to technical or observational failure. 
These failures may lead to interval carcinomas afterwards. Moreover, interval carcinomas may 
occur due to failure in biopsy technique leaving the suspected area in situ or by misinterpreting 
histopathology of the tissue removed. Several authors suggest close follow-up after excisional 
biopsies for benign breast lesions.
In chapter 9 the number of operative procedures for malignancies or benign abnormalities during 
follow-up of patients initially operated for benign breast lesions detected during screening, or not 
operated after a false-positive screening, is evaluated.
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After a screening round many radiologically suspect lesions that are removed wih an excisional 
biopsy turn out to be benign. These lesions are defined as false-positive results of the breast 
cancer screening program. Excision of benign lesions can lead to severe anxiety in patients and 
increased costs of health care. Follow-up of these lesions by mammography as suggested by 
some authors will overstretch a surgical outclinic and induce increased health care costs as well. 
In chapter 10 we evaluated follow-up methods of patients with a false-positive screening result 
in order to determine which method of follow-up is most useful.
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Screen detected 
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Summary
Background; We know that screening for breast cancer leads to detection of smaller 
tumours with less lymph node metastases. Could it be possible that the decrease in 
mortality after screening is not only caused by this earlier stage, but also by a different 
Mitotic Activity Index (MAI) of the tumours that are detected by screening? Is MAI a 
prognostic factor for recurrence-free survival?
Method; A retrospective study of 387 patients with breast cancer, treated at the University 
Hospital Nijmegen between January 1992 and September 1997. Ninety patients had 
screen detected breast cancer, 297 patients had breast cancers detected outside the 
screening program. The MAI, other prognostic factors, and recurrence-free survival were 
determined.
Results;  In non-screen detected tumours the MAI is twice as high as in screen detected 
tumours, even after correction for age took place. The MAI correlated well with other 
tumour characteristics. The MAI in itself is a prognostic factor for recurrence-free 
survival.
Conclusion;  Favourable outcome in screen detected breast cancer is not entirely caused 
by detecting cancer in early stages: quantitative features such as the MAI indicate a less 
malignant character of screen detected breast cancer.
The MAI is an independent prognostic factor for recurrence-free survival.
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Introduction
Screen detected breast cancer patients show a better survival than breast cancer patients who are 
detected outside the screening program (19,27,36). According to the early results of the Dutch 
trial in Nijmegen the breast cancer mortality rate in women of 35 and over can be reduced by 
roughly 50% by regular mammographic screening of all eligible women (35). Other studies 
showed similar results since then (26,30). This is mainly explained by early detection of screen- 
detected tumours. It may, however, be possible that other factors than tumour size are 
responsible for better survival figures. Screen detected cancers may be less aggressive than non­
screen detected cancers. One way to determine tumour aggressiveness is to measure the Mitotic 
Activity Index (MAI). The MAI is an index made out of the mitotic frequency in the most active 
part of the tumour, and therefore is a quantitative feature of the tumour. In recent literature 
quantitative factors, such as the MAI, are good prognostic factors for patient survival 
(1,3,4,10,21,22,23,31,32,34). They discriminate very well less aggressive tumours from more 
aggressive ones. Measuring the MAI is easily learned and can be performed in a highly 
reproducible way if a strict protocol is carefully followed (9,10,20).
The aim of this study was to investigate whether there is a difference in the MAI 
between screen and non-screen detected breast cancers, and to evaluate the prognostic 
value of the MAI for recurrence free survival, adjusting for other prognostic factors.
Patients and methods
A retrospective evaluation was performed of 387 evaluable patients with breast cancer who were
treated between January 1992 and September 1997. The median period of follow up was 2.6
years (range 0.2-6.2). Ninety patients with a mean age of 58 years (range 48-72 years), had
screen detected breast cancer, while 297 patients with a mean age of 54 years (range 28-93
years), had non-screen detected breast cancer. Breast cancer screening was usually performed in
the age group 50-70 years. Patients were surgically treated with a modified radical mastectomy
(n=305, 79%) or a breast saving procedure (n=82, 21%). Radiotherapy was used in breast saving
procedures (21%) and in case of T3/T4 tumours or chest-wall contamination (11%). Adjuvant
irradiation of the axilla was used when there was extranodal involvement (15%). Radiotherapy
was used in screen and non-screen detected patients in the same frequency. Use of adjuvant
chemotherapy was depending on lymph node involvement and menopausal status. Chemotherapy
was given as CMF (cyclophosphamide, 100 mg/m orally on days 1 to 14; methotrexate, 40 
2 2  mg/m intravenously on days 1 and 8; and fluorouracil, 600 mg/m intravenously on days 1 and
8) in 105 patients (27%). Use of adjuvant chemotherapy was not different for screen or non­
screen detected patients. Hormone treatment in the form of adjuvant tamoxifen 20 mg/day for a 
period of 5 years was given to 79 patients (20%), according to receptor status, menopausal status 
and lymph node status. Use of hormone treatment was equal over groups of screen and non­
screen detected patients. The pathologist determined tumour size, histological type, 
differentiation grade, hormone receptor status, and lymph node involvement. Grading of the 
invasive carcinoma was carried out according to the Elston method described in Diagnostic 
Histopathology of the Breast by Page and Anderson (16). The method involves the assessment of 
three components of tumour morphology: tubule formation, nuclear pleomorphism and frequency 
of mitoses. Tubule formation was scored as 1 if the great majority of the tumour was composed
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of formed tubules. When tubule formation was seen in moderate amounts, a score of 2 points was 
made. Where little or no tubule formation was seen, the score was given as 3 points. For nuclear 
pleomorphism a score of 1,2, or 3 was given if the tumour cells showed little, moderate or strong 
variation in shape and size of the nuclei respectively. Counting the number of mitoses in 10 high 
power fields assessed the mitotic rate. Less than 10 mitoses were given 1 point, 10-19 mitoses 
were given 2 points, and 20 mitoses or more were given 3 points. Adding the three scores 
together gave the histological grade of differentiation. Tumours were considered well 
differentiated (grade I) if the total score was 3-5 points (n=76, 19%), moderately differentiated 
(grade II) with a score of 6-7 points (n=157, 40%), and poorly differentiated (grade III) if the 
score was 8-9 points (n=161, 41%). The MAI was assessed in the subjectively most cellular and 
proliferate area of the tumour, usually at the periphery of the tumour, avoiding regions of necrosis 
and inflammation. The mitosis counting was performed using a Leitz microscope at x400 
magnification (x10 ocular and x40 objective with a numerical aperture of 0.70 and a field 
diameter of 525 ^m). The MAI was determined by counting the mitoses in 10 consecutive high 
power fields (20).
Statistical methods
Differences in geometric means of the MAI between groups were tested for significance after 
logarithmic transformation of the MAI. This was performed with a one-way analysis or a t-test 
depending on the number of groups. The difference in MAI between screen detected and non­
screen detected cancers was adjusted for other tumour characteristics, being tumour size, lymph 
node involvement, lymph vessel invasion, blood vessel invasion, and hormone receptor status by 
multiple regression analysis.
Recurrence free actuarial survival curves were computed for tumours with MAI from 1-9, 10-24, 
and above 24. The relation between the MAI and recurrence free survival was adjusted for other 
tumour characteristics and detection mode by a proportional hazards model.
A significance level of 0.05 was used.
Results
In patients who were not screen detected (n=297), there was no difference in the MAI between 
148 patients younger than 50 years and 149 patients of 50 years or older.
Because the patients in the non-screen detected group were younger, the non-screen detected 
group was matched for age with the screen-detected group by selecting all patients from 50 to 70 
years old. We choose this group because in the screening group the majority of patients were 
between 50 and 70 years (82/90). After adjusting for age 176 of 387 screen and non-screen 
detected patients remained between 50 and 70 years old. The patients’ characteristics of these 
groups are given in table 1. In this group the ratio of the geometric means of the MAI in the non­
screen detected versus screen detected remained 2.0 (confidence interval 1.4-2.8, p<0.0001). The 
geometric mean of the MAI in the screen-detected group was half the geometric mean of the non­
screen detected group (6 versus 12, p<0.0001), even after stratification for T and N stages. Only 
in N1 patients from 50-70 years the MAI was not significantly different (table 2).
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The MAI correlated well with other important tumour factors, such as histological type, lymph 
vessel invasion, blood vessel invasion, tumour size and lymph node involvement, and receptor 
status. (Table 3)
After adjustment for mode of detection, tumour stage (T), lymph node involvement (N), lymph 
vessel invasion, blood vessel invasion and hormone receptor status in a multivariate analysis, the 
MAI remained a strong independent prognostic factor for recurrence of disease.
Table 1: Patients characteristics o f  176patients between 50-70years.
Screen detected non-screen detected
Number 82 94
Mean Age 58 (50-70) 58 (50-70) ns
Follow-up (years) 2.7 (0.3-5.9) 2.7 (0.3-5.9) ns
MAI (median) 6 12 p<0.001
Tumor stadium
T1 51/82 35/94
T2 27/82 38/94
T3 1/82 9/94
T4 3/82 12/94
NO 56/82 38/94
N1 24/82 48/94
N2 2/82 3/94
Unknown 0/82 5/94
Mastectomy 55/82 77/94 ns
Adjuvant treatment
Chemotherapy 11/82 18/94 ns
Hormone therapy 18/82 25/94 ns
Radiotherapy 32/82 50/94 ns
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The Risk Ratio for recurrence of disease after adjustment for all variables in a multivariate 
analysis was 1.01 (p<0.04).
After adjustment for T, N, lymph vessel invasion, and blood vessel invasion in a multivariate 
analysis of all patients between 50 and 70 years, the ratio of the geometric means of the MAI was 
1.7 (confidence interval 1.2-2.4, p<0.0004). After adjustment for hormone receptor status, the 
ratio was 1.4 (confidence interval 0.95-1.9, p<0.09), indicating that even after correction for these 
prognostic factors, the MAI is higher in the non-screen detected than in the screen detected 
patients with breast cancer.
The 5-year recurrence-free survival was 90% in the screen-detected group, versus 67% in the 
other group. Also the MAI was a significant univariate prognostic factor for recurrence-free 
survival (figure 1).
Table2: M AI fo r  screen and non-screen detected cancers, stratified fo r  T and N  stages, all 
patients between 50-70 years. n=number o f  tumours.
Screen
MAI
geometric mean (P25-P7 5) 
Non-screen
p-value
Overall 
(all ages)
6 (3-16) 
n=90
12 (6-29) 
n=297
p<0.0001
Tumor size
T1 6(3-15)
n=51
12(6-36)
n=35
p=0.004
T2 6(2-19)
n=27
14(6-27)
n=38
p=0.03
Nodal status
N0 5(2-13)
n=56
11(5-23)
n=38
p=0.0009
N1 9(5-20)
n=24
12(6-29)
n=48
p=0.28 (ns)
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Discussion
Screening for breast cancer is an effective method to detect breast cancer in an early stage of 
disease. Clinical breast examination and mammography are recommended as combined 
modalities for breast cancer screening (18). The use of supplemental ultrasound has been 
advocated in patients with radiographically dense breasts, but there appears to be no significant 
contribution to the accuracy of the work-up (24). In the Netherlands the screening program has 
been introduced in the whole country for women between 50 and 70 years old (17). Population 
survey in younger women seems to be less beneficial ( 15,19,25,29).
Recently the age for screening in the Netherlands has been increased up to 75 years, because a 
reduction in breast cancer mortality due to mammographic screening has been shown for women 
aged up to 75 years (13,14). A breast cancer-screening program leads to an increased use of 
breast conserving therapy and an increased need for postoperative radiotherapy; there will also be 
a higher number of women diagnosed with non-invasive breast cancer (8). As we showed before 
(28), also in this study the screen detected tumours were more often in an earlier stage than the 
tumours detected outside the screening program. The recurrence free survival in patients with 
tumours detected in the screening program was significantly better compared to patients with 
tumours detected outside the screening program. The finding that the MAI was low in the screen 
detected group supports the idea that screen detected tumours are generally more favourable than 
others, because they are growing more slowly and are detected with mammography earlier for 
that reason. We considered only the MAI and not other factors that contribute to differentiation 
grade of the tumour. The length time bias, caused by this phenomenon, has always been a point 
of controversy in uncontrolled breast screening projects. Our study makes clear that this bias is 
certainly not only of theoretical importance. That the low MAI is found not only in T1 tumours, 
but also in T2 indicates that T2 tumours detected outside the screening programs are of a 
different biological behaviour. The large size of the tumour is per se not a prognostic factor but 
the MAI of it is.
The MAI itself is an important prognostic factor for recurrence free survival. We were able to 
corroborate other studies that the MAI correlates well to other prognostic factors. The prognostic 
importance is even better when the MAI is used in other scoring systems, such as the Multivariate 
Prognostic Index (MPI), which combines the MAI, lymph node status, and tumour size (22). We 
found that the MAI alone is an important predictor for disease free survival.
The MAI is a factor that can attribute to predicting poor responders to chemotherapy (12). Others 
suggested that the decisions on adjuvant therapy in breast cancer could be based on the MAI and 
the MPI, particularly in node negative patients (1,5,7). Assessing morphometric features of a 
resected specimen of breast cancer should be incorporated in routine pathology reports (6,22). 
Regional differences in prognosis of breast cancer are correlated with the MAI and other 
microscopic features (6).
According to Jannink et al (1995) counting the MAI as we described before gives the strongest 
prognostic value (20). Collan et al give an efficient description of the method and its reliability 
(9). It takes about 10 to 15 minutes extra time to calculate the MAI in a tumour. It can be learned 
within a reasonable time to perform mitosis counting in a highly reproducible manner in a routine 
setting. However, motivation and ongoing quality control are essential to guarantee the 
reproducibility of the assessments (10,11)
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Table 3: Relation o f  the M AI with other prognostic factors.
Factors
geometric mean
n MAI P-value
Histological type
ductal 272 13
lobular 53 4
tubular 12 1
medullar 6 45
mixed type 
rest
36
8
8 0.001
Lymph vessel invasion
positive 195 7
negative 190 16 <0.001
Blood vessel-invasion
positive 24 20
negative 361 10 0.007
T-stage
T1 153 8
T2 145 12
T3 33 15
T4 51 13 0.005
N-stage (nodal status)
N0 180 8
N1 187 13
N2 7 20 <0.001
Oestrogen receptor status
positive 25 9
negative 82 18 <0.001
Progesterone receptor status
positive 26 9
negative 100 20 0.002
As far as we know there is no previous study that investigated the MAI in relation to the mode of 
detection of breast cancer. Tumours detected by screening have a significant lower MAI than 
tumours detected outside the screening program. This implies that these tumours have a different
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profile, even when they have the same stage of disease. Besides the fact that screen detected 
tumours are detected earlier, they are also equipped with a favourable MAI, thus leading to a 
better prognosis.
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Abstract
Background and objectives: Since a breast cancer-screening program has started, many cancers 
are detected due to this program. However, tumours are also detected in between two 
mammographic screening rounds, after a previous negative screening result. These interval 
tumours have an intermediate outcome. The Mitotic Activity Index (MAI) is a strong prognostic 
factor for disease free survival. The MAI is lower in screen-detected tumours, indicating a less 
aggressive biological behaviour in this group. In this study the MAI is compared between screen- 
detected, interval and symptomatic breast cancers.
Methods: Between 1991 and 1999, the MAI was determined in 581 breast cancers, 160 (28%) 
detected by screening, 66 (11%) were interval carcinomas, and 355 (61%) were symptomatic 
breast cancers. Besides MAI other prognostic factors were registered.
Results: The interval group had a significantly higher median MAI (17-18, range 1-134) than the 
screen detected group (7-8, range 0-94, p<0.0001), but there was no difference with the 
symptomatic group (MAI 15, range 0-149, p=0.92). Interval cancers had an intermediate outcome 
for other prognostic factors, compared to screen detected and symptomatic cancers.
Conclusions: Interval breast cancers have a higher MAI than screen detected breast cancers, 
indicating a more aggressive biological behaviour. The MAI however is not higher than in the 
symptomatic group.
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Introduction
In the Netherlands a nation-wide screening program for breast cancer has been started in 1990, 
providing a biennial screen examination of women aged 50 to 69 years. This program has been 
implemented successfully [1]; recently the upper age limit for screening was expanded to 74 
years. Breast cancers are detected at an earlier stage of disease [2]. Nevertheless tumours are also 
detected in between two mammographic screening rounds, after a previous negative screening 
result. These tumours are called interval carcinomas. The fact that these interval carcinomas arise 
relatively shortly after a normal mammogram has led to speculations about an aggressive 
behaviour of these tumours. On the other hand several authors report that interval carcinomas do 
not have a worse prognosis compared to symptomatic carcinomas. In fact interval carcinomas 
showed an outcome intermediate between patients with screen detected breast cancers and 
patients with cancers detected outside the screening program [3,4,5,6,7,8].
The Mitotic Activity Index (MAI) is a strong prognostic factor for disease free survival. In a 
previous study from the same institute a significant lower MAI was determined in screen- 
detected breast cancers then in breast cancers in the same stage, detected outside the screening 
program, suggesting a less aggressive behaviour of screen-detected breast cancers [9].
The present study was undertaken to find out if interval carcinomas have a MAI in between the 
screen detected and symptomatic carcinomas, or if they have a higher MAI, indicating a more 
aggressive biological behaviour.
Patients and methods
Between 1991 and 1999 581 patients received their primary treatment for breast cancer at the 
Department of Surgery of the University Medical Centre Nijmegen. Hundred and sixty patients 
(28%) were detected after breast cancer screening, 66 patients (11%) had interval carcinomas and 
355 patients (61%) had symptomatic breast cancers, not detected with screening for breast 
cancer. Patient and treatment characteristics as well as clinical tumour stages are given in table I. 
In the Nijmegen area screening for breast cancer is also performed in younger and older patients 
(from 45 years-no upper age limits) than in the nation-wide screening program, because 
screening in this area has an experimental setting. This explains the large age-range.
The MAI was assessed in the subjectively most cellular and proliferate area of the tumour, 
usually at the periphery of the tumour, avoiding regions of necrosis and inflammation. The 
mitosis counting was performed using a Leitz microscope at x400 magnification (x10 ocular and 
x40 objective with a numerical aperture of 0.70 and a field diameter of 525 |lm). The MAI was 
determined by counting the mitoses in 10 consecutive high power fields [10].
Other prognostic factors that were evaluated are menopausal state, tumour size, histological 
tumour type, lymph vessel invasion, blood vessel invasion, lymph node status and receptor status. 
Several statistical analyses were performed with the use of a Statistical Analysis System (SAS) 
by the department of Epidemiology and Biostatistics of the University Medical Centre Nijmegen.
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Table I; Patient characteristics in 581 patients with breast cancer; screen-detected, interval and 
symptomatic breast cancers are compared.
Screen Interval Symptomatic
(n=160) (n=66) (n=355)
Age (median) 60 (46-93) 56 (45-84) 48 (26-95)
Stage
T1 (%) 98 (61) 30 (45) 113 (32)
T2 (%) 54 (34) 24 (36) 165 (46)
T3 (%) 8 (5) 12 (l8) 75 (21)
N0 (%) 99 (62) 36 (55) 137 (39)
N1 (%) 56 (35) 25 (38) 201 (57)
Treatment
Breast conserving 62 (39%) 16 (24%) 60 (17%)
Mastectomy 98 (61%) 50 (76%) 295 (83%)
Results
In table II the post-operative tumour characteristics and prognostic factors are compared between 
the three groups.
Tumour size is smaller for screen-detected tumours, while interval cancers and symptomatic 
cancers are similar.
The nodal status (p=0.001), blood vessel invasion (p=0.182) and lymph vessel invasion 
(p=0.001) show an intermediate percentage for the interval cancers. Interval cancers less often 
display ductal types of cancers compared to the other two groups (p=0.002). Progestogen 
receptor status (PR) is similar for all groups, while the oestrogen receptor status (ER) has 
significant differences in favour of the screen-detected group (P=0.01).
The median MAI in the screen-detected group was 7-8 (0-94), in the interval group 17-18 (1-134) 
and in the symptomatic group 15 (0-149). The distribution of the MAI is plotted in figure 1. The 
interval group has a significantly higher median MAI than the screen detected group (P<0.0001), 
but there is no difference with the symptomatic group (P=0.92). When the MAI in the different 
groups is corrected for tumour stage, there are still differences (table III). In the T1 subgroup 
there is a difference in the MAI between screen detected and interval cancers (p=0.03) and 
between screen detected and symptomatic cancers (p=0.03), but no difference between interval 
and symptomatic cancers (p=0.31). In the T2 subgroup there also was a difference in the MAI 
between screen detected and interval cancers (p=0.05) and screen detected and symptomatic 
cancers (p=0.009), but no difference between interval and symptomatic cancers (p=0.65). In the 
T3 subgroup and the N1 subgroup there were no differences. In the N0 subgroup again
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differences were found between screen detected and interval cancers (p=0.0005) and screen 
detected and symptomatic cancers (p=0.0002), while no differences could be found between 
interval and symptomatic cancers (p=0.11).
Table 2: Patient and tumour characteristics fo r  breast cancer patients. Screen detected cancers, 
interval cancers and symptomatic breast cancers are compared.
Screened Interval Symptomatic P-value
Tumour size
• <2 cm 67% 45% 34%
• >2 cm 33% 55% 66% <0.001
Nodal status
• NO 68% 58% 42%
• N1/N2 32% 42% 58% <0.001
Lymph vessel invasion
• Negative 68% 55% 45%
• Positive 32% 45% 55% <0.001
Angio invasion
• Negative 97% 95% 93%
• Positive 3% 5% 7% 0.182
Histology
• Ductal type 72% 55% 75%
• Lobular type 15% 24% 18%
• Other/mixed types 13% 21% 7% 0.002
ER-status
• Positive 85% 7O% 72%
• Negative 15% 30% 28% 0.01
PR-status
• Positive 92% 73% 70%
• Negative 8% 27% 30% 0.9
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Discussion
Schroen et al. found that the 5-year and 10-year disease free survivals for breast cancer in the 
interval group were significantly better than the 5-year and 10-year survivals in the patients 
detected outside the screening program. In their study no significant difference was found with 
the screen detected group. In fact the interval group has an intermediate prognosis. Patients in the 
study of Schroen were treated in the period between 1975 and 1990 [3]. In the present study from 
the same institute with patients treated between 1991 and 1999 the MAI from the interval group 
is similar with the MAI from the group detected outside the screening program, and significantly
Figure 1; Distribution o f the M AI in screened, interval and symptomatic breast cancers.
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Table 3: Median M AI compared in three groups, according to tumour stage
Screened Interval Symptomatic p-value
T1 6 13 10 0.02
T2 12.5 25 21 0.02
T3 11 12 18 0.33
NO 5 19.5 12 0.0001
N1 15.5 18 20 0.25
higher than the MAI in the screen-detected group, even after correction for tumour stage. Only in 
larger tumours (T3) and lymph node metastases (N1) there was no difference in MAI between the 
three groups. Since in previous studies from the same institute the MAI turned out to be a 
significant prognostic factor for disease-free survival [9], we would expect that the disease-free 
survival in the interval group would be similar to the disease-free survival in the symptomatic 
group. Other authors described similar survival rates between interval and symptomatic cancers 
[7]. In the present study the mean follow up period is too short to compare overall survival and 
disease-free survival with the previous study from the same institution by Schroen et al.
In studies that focussed on tumour characteristics for malignant potential a selected subgroup of 
highly malignant tumours in the interval cancer group was found, while the whole interval 
cancer group was heterogeneous [11]. Although the MAI is an indicator of malignant potential, 
the distribution of the MAI in the groups with screen detected, interval and symptomatic cancers 
does not show such a subgroup in interval carcinomas in our material (figure 1). A possible 
explanation for this lack of more aggressive tumours is that interval cancers are cancers that are 
‘missed’ during screening and therefore do not have a more aggressive behaviour. On the other 
hand some studies show a more aggressive behaviour of tumours that are not detectable with the 
use of mammography, which should lead to a worse prognosis in ‘missed’ interval breast cancers 
[12]. Another possible explanation for a less aggressive behaviour is that patients who attend 
screening are more alarmed by symptoms on self-examination, leading to detection of interval 
carcinoma in a more favourable stage [13]. The screen detected breast cancers have a lower MAI 
[9], confirming hypothesis of length-bias sampling of a subgroup of cancers with a proportion of 
slow-growing tumours. The interval cancers have a MAI comparable with the symptomatic breast 
cancers, indicating a similar biological behaviour as symptomatic breast cancers. When there is a 
long delay before a tumour is detected, there is a dedifferentiation that can lead to a worse 
prognosis. Tinnemans et al. found that a significant shift in receptor phenotype was observed 
from non-palpable breast cancer (71%) via palpable breast cancer (58%) and locoregionally 
advanced primary breast cancer (48%) to first metastatic breast cancer (41%). This is an 
indication for a less differentiated and more aggressive biological behaviour of more extensive 
breast cancer [14].
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Conclusion
The MAI in interval breast cancers was found to be higher than the MAI in screen-detected breast 
cancer and was as high as the MAI in symptomatic cancers. Overall and disease-free survival in 
these interval patients must be studied to elucidate the value of the MAI in predicting the 
prognosis of these patients.
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Abstract
It is the purpose of this study to investigate whether breast cancer in patients with a positive 
family history is detected at an earlier stage with better prognostic markers than breast cancer in 
patients without a positive family history. In 481 patients tumour size, tumour type, lymph vessel 
invasion, blood vessel invasion, receptor state, lymphatic spread, MAI and survival were 
measured and compared, according to their family history.
No difference was found between patients without a family history, patients with first-degree 
relatives or patients with second-degree relatives with breast cancer. Tumours were detected in 
the same stages and prognostic factors, MAI and survival were similar in all groups.
At this moment a positive family history of breast cancer does not lead to earlier detection of 
breast cancer or a better survival.
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Introduction
Familiality is one of the risk factors associated with the development of breast cancer. In 1987 a 
study was published indicating that women with a familial risk of breast cancer do not attend 
specialist care earlier than other women. The clinical presentation and survival of patients with a 
positive family history were not different from that of patients without a positive family history 
(1). Other evidence exists that after introduction of a population screening for breast cancer, 
screened women with breast cancer who, in retrospect, turn out to have a family history of breast 
cancer are staged in the same stages as women with breast cancer, discovered under close 
surveillance because of a positive family history. Thus indicating no advantage of the knowledge 
that an increased risk exists (2).
The Mitotic Activity Index (MAI) is a strong single prognostic factor that is lower in screened 
breast cancer patients in a similar stage as control patients, indicating a different biological stage 
of the cancer found with breast cancer screening (3). We would like to know whether also 
familiality leads in similar stages of disease to a different MAI compared to patients without a 
family history, suggesting a different biological behaviour of these tumours. In the following 
study the relationship between familiality and clinical presentation, MAI and survival are studied.
Patients and methods
All patients who received their primary surgical treatment for breast cancer at the Department of 
General Surgery from the University Medical Centre Nijmegen in Nijmegen during the period 
1991-1996 were included in the study. Most patients had symptomatic breast cancer (71%), in 
29% the breast cancer was detected with screening methods. In 481 women the family history 
and clinical appearance of breast cancer were registered. The pathologist determined tumour size, 
histological type, differentiation grade, hormone receptor status, and lymph node involvement. 
Grading of the invasive carcinoma was carried out according to the Elston method described in 
Diagnostic Histopathology of the Breast by Page and Anderson (4). The method involves the 
assessment of three components of tumour morphology: tubule formation, nuclear pleomorphism 
and frequency of mitoses. Tubule formation was scored as 1 if the great majority of the tumour 
was composed of formed tubules. When tubule formation was seen in moderate amounts, a score 
of 2 points was made. Where little or no tubule formation was seen, the score was given as 3 
points. For nuclear pleomorphism a score of 1,2, or 3 was given if the tumour cells showed little, 
moderate or strong variation in shape and size of the nuclei respectively. Counting the number of 
mitoses in 10 high power fields assessed the mitotic rate. Less than 10 mitoses were given 1 
point, 10-19 mitoses were given 2 points, and 20 mitoses or more were given 3 points. Adding 
the three scores together gave the histological grade of differentiation. Tumours were considered 
well differentiated (grade I) if the total score was 3-5 points (n=76, 19%), moderately 
differentiated (grade II) with a score of 6-7 points (n=157, 40%), and poorly differentiated (grade 
III) if the score was 8-9 points (n=161, 41%). The MAI was assessed in the subjectively most 
cellular and proliferate area of the tumour, usually at the periphery of the tumour, avoiding 
regions of necrosis and inflammation. The mitosis counting was performed using a Leitz 
microscope at x400 magnification (x10 ocular and x40 objective with a numerical aperture of 
0.70 and a field diameter of 525 ^m). The MAI was determined by counting the mitoses in 10 
consecutive high power fields (5).
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A negative family history occurred in 318 women (66%), while in 103 women (21%) one or 
more first-degree relatives or both first and second-degree relatives and in 60 women (12%) one 
or more second-degree relatives were treated for breast cancer.
The group of patients with first degree and the group of patients with second degree relatives 
with breast cancer were compared with the other group with respect to age, tumour size, 
differentiation grade, tumour type, receptor status, lymphatic spread, MAI and survival.
Results
The median age in the non-familial group was 54.8 years (range 31-84) in the first-degree group 
53.6 years (range 30-82) and in the second degree group 49.9 years (range 27-82). The age in 
second-degree relatives was found to be significantly lower (p<0.0012) than in the two other 
groups of patients together. Because of the lower age in patients with second-degree relatives 
with breast cancer, it is not surprising that these patients were more often premenopausal 
(p<0.002).
Invasive ductal cancer was detected in 73% (351 patients), invasive lobular cancer in 18% (87 
patients) and other types in 9% (43 patients). There were no differences between the three groups 
(p<0.249). Also tumour size was not significantly different between the groups (p<0.181). Other 
factors such as differentiation grade, lymph vessel invasion, angio-invasion, oestrogen receptor 
status and progestogen receptor status were also comparable in the different groups.
The important prognostic factors such as MAI and lymphatic spread were not different in the 
three groups (table 1).
Table 1: M AI and lymphatic spread, related to familiality o f breast cancer.
No relatives 
N=318
First-degree
N=103
Second degree 
N=60
MAI (median) 11 (0-116) 11 (0-149) 12 (0-83) ns
Number of nodes 
(median)
15 17 16 ns
Lymphatic spread 148 (47%) 42 (41%) 33 (55%) ns
Number of positive 
Lymph nodes 
(median)
3 3 3 ns
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Overall survival (p<0.8224) and disease free survival (p<0.2761) were similar in the groups, 
neither was there a higher incidence of locoregional or systemic recurrence in either of the groups 
(p<0.466) (figures 1 and 2).
Figure 1: Overall survival in 481 breast cancer patients, stratified according to family-history
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Figure 2: Disease-free survival in 481 breast cancer patients, stratified according to family- 
history
Discussion
The knowledge that a female family member had breast cancer did not lead to detection of breast 
cancer in a more favourable stage, leading to a better prognosis. In comparison with data from the 
same institution in 1987, not much has changed, in spite of the conclusion made then, that the 
group of women with a positive family history of breast cancer needs to be instructed (1). Others 
found that familial history of breast cancer was an independent predictor for a favourable 
prognosis in premenopausal patients, caused by detection in a more favourable stage (6). A meta­
analysis by Chappuis et al. was performed to study the impact of family history on breast cancer
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survival. They found conflicting data in the existing literature as to whether the prognosis of 
familial or hereditary breast cancer differs from that of sporadic cases; only BRCA1 seems to be 
related to a worse prognosis (7). Others tried without success to detect prognostic factors in 
BRCA1 and BRCA2-associated breast tumours (8). Verhoog et al. found that disease-free and 
overall survival were similar for sporadic and hereditary breast cancer in the presence of different 
tumour characteristics (9). In the Netherlands a recommended surveillance schedule with 
monthly breast self-examination, semi-annual examination by a physician and yearly 
mammography from 25 years onwards is used when an estimated risk of development of breast 
cancer of 20% exists (10). A cumulative risk of development of breast cancer over 30% is an 
indication for genetic counselling (12). Possible options for relatives of breast cancer patients are: 
enrolment in a surveillance program, participation in a chemoprevention trial or prophylactic 
mastectomy (11). Surveillance programs, where women with a positive family history are closely 
observed, have led in two studies to earlier detection of breast cancer and to a decrease of breast 
cancer mortality (2,11). In this study women were not in a standard close surveillance program. 
Although all women in the two groups that are concerned were aware of a positive family history 
the several prognostic factors that were registered did not show a significant difference between 
these two groups and the group of patients without a positive family history. These finding 
indicate that the women with a positive family history of breast cancer did not present themselves 
at an earlier stage of disease. Possibly this effect can be attributed to the running of a breast 
cancer screening program at the time of the study. During the whole period of the study the 
Nijmegen area participated in a breast cancer screening program in which mammography was 
performed every other year. If  indeed this were the explanation of our results, than it would be 
justified to return all patients with a positive familial history to the breast cancer-screening 
program, except for those with BRCA 1 or 2 genetic inheritances. This would result in a 
significant reduction in financial costs as well as would prevent the anxiety and psychological 
burden imposed on the women participating in a close family surveillance program (13).
The study by Tilanus-Linthorst et al., where women with a positive family history were under an 
intensive surveillance program, did find a decrease in prognostic worse stages of breast cancer 
compared to women with a positive family history who were not under surveillance. However, in 
patients with breast cancer detected by the breast cancer-screening program a similar stage 
reduction is achieved. Hence, for patients over 50 years with a positive family history the normal 
breast cancer-screening program would probably be sufficient enough. Still, for screening of 
younger patients with a positive family history of breast cancer, a mortality reduction can be 
accomplished by performing a close surveillance starting some years before the youngest age of 
onset of breast cancer in the family (2). The use of Magnetic Resonance Imaging (MRI) in a 
surveillance program of these younger women should be further explored. (14). MRI shows a 
higher sensitivity than mammography in detecting breast cancer lesions (15). At this moment 
several multicenter trials, evaluating the value of MRI in screening for breast cancer, are 
conducted worldwide.
Conclusion
The knowledge of having family members with breast cancer had no effect on the detection of 
breast cancer regarding to stage, MAI or patient survival. The fact that the MAI, which proved a 
strong prognostic factor in our earlier work, as well as overall survival were identical in all three 
groups indicates that biological behaviour of the tumours detected in patients with a positive
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family history is not different from those tumours detected in patients without a positive family 
history. Moreover, our data strongly suggest that for patients with a positive family history, other 
than BRCA associated, no special screening is mandatory as long as they take part in a breast 
cancer-screening program consisting of mammography every other year. For patients of younger 
age who fall outside such screening program, close surveillance starting some years before the 
youngest age of onset of breast cancer in the family is still recommended.
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Abstract
Objective; Determine which factors contribute to tumour-positive margins in patients who 
underwent a lumpectomy as the initial stage in the treatment of breast cancer.
Design; Descriptive, prospective
Setting; January 1998-December 1999, IJsselland Hospital, the Netherlands 
Patients; 110 women, median age 62 years (26-88)
Interventions; Reoperations, pathological evaluation of specimen sampled 
Main outcome measures; positive margins, reoperations, residual tumour in reexcision specimen 
Results; Diagnostic intentions (p=0.015), larger tumours (p=0.023), multifocal tumours 
(p=0.0014), tumours with positive margins (p=p<0.05) and tumours with an extensive in situ 
component (p=0.02) all were risk factors for reexcision. Residual tumour was more often found 
in younger patients (p=0.03), after a diagnostic excision (p=0.05), when the primary tumour 
consists of DCIS only (p=0.0085), after a smaller primary tumourectomy (p=0.0051), with worse 
differentiation (p=0.033), in multifocal tumours (p=0.0026), after a positive margin (p=0.011), or 
with an extensive in situ component (p=0.0044).
Conclusions; Many risk factors for reoperation and residual tumour after lumpectomy for breast 
cancer can be identified, however wire localisation biopsy is not one of them.
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Introduction
Breast cancer screening generally leads to detection of early stage breast cancers. A great part of 
the detected tumours are non-palpable and are only detected by mammography. The patients are 
preferably treated by lumpectomy or quadrantectomy followed by radiotherapy, instead of a 
modified radical mastectomy, as a breast saving procedure is considered to lead to similar results 
on survival and local recurrences (16).
The results of local excision followed by radiotherapy as to local control are significantly better 
when the surgical margins of the excised palpable or non-palpable tumour are clearly negative. A 
microscopic positive margin remains to be a significant risk factor for local recurrence in the 
conservatively treated patients (5,6).
The aim of this study is to determine which factors may possibly contribute to tumour-positive 
margins, reexcision and residual tumour in patients who underwent a lumpectomy as the initial 
stage in the treatment of breast cancer.
Patients and methods
All female patients who underwent a lumpectomy for invasive or non-invasive breast cancer 
between January 1998 and December 1999 in the IJsselland Hospital were prospectively 
included. The median age of the 110 women was 62 years (26-88). In eighty-one patients (74%) 
the tumour was palpable, 29 (26%) non-palpable. Wire-localisation with the use of 
mammography or ultrasound was performed in 44 patients (40%). In 27 patients (25%) in whom 
the diagnosis was known on basis of cytological or histological findings an initial curative 
excision was performed, while in 83 patients (75%) the procedure had a diagnostic character. 
After a wire localisation a specimen radiography was performed.
The following parameters were investigated in relation to the surgical margins: tumour size, 
weight of the excised specimen, palpability of the tumour, wire-localisation, (extensive) in situ 
carcinoma component, age, multifocality and grade of differentiation.
The pathologist performed tumour size and weight measurements.
A margin was considered to be focally positive if tumour-cells could be detected within 1 mm 
from the surgical margin. Grading of differentiation of the invasive carcinoma was carried out 
according to the Elston method (3).
In all patients with a focally or massive irradical margin for invasive or non-invasive breast 
cancer or poorly or moderately differentiated in situ carcinoma a reexcision was done. 
Consequently the number of recurrent operations was also determined as an outcome measure. 
Moreover the finding of residual tumour in the resected specimen after the secondary procedures 
was taken into consideration.
All statistical analyses were performed with NCSS 2000, using multi-variant analysis, student-t 
test and chi-square testing functions.
Results
In 59 of 110 women (54%) a second procedure was performed according to the rules used in our 
hospital. In five patients this was a re-excision (8.5%), in 12 (20.3%) a simple mastectomy and in
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42 (71.1%) a modified radical mastectomy. The reason for the reoperation was in most cases the 
margin status, multifocality, or refusal of a breast conserving therapy.
Table 1 shows that a tumour excision after wire-localisation was more often performed in older 
patients with non-palpable tumours. This type of biopsy was mostly a diagnostic procedure and, 
depending on the indication, revealed more often an in situ component than an excision 
procedure of a palpable tumour. The tumours that are found after wire-localisation were usually 
smaller. However, the weights of the resected specimen, the margin status, the focality and the 
differentiation were statistically not significant.
Table 1; Characteristics o f differences between excision ofpalpable and non-palpable tumours.
Lumpectomy
n=66
Wire localised 
n=44 p-value
Age (median) 53.5 59.5 0.05
Palpability 63(95%) 18(41%) <0.05
Tumour type CIS
Combined
18(27%)
41(62%)
8(18%)
22(50%) 0.02
Diameter (histology, median) 15 mm 10 mm 0.0069
pT-stage Tis 
T1 
T2 
>T2
Unknown
7(11%)
39(59%)
19(29%)
1(2%)
14(32%)
23(52%)
4(9%)
1(2%)
2(5%) <0.05
Weight of specimen (median) 47.5 gram 44.5 gram 0.41
Differentiation good
moderate
poorly
Unknown
8(12%)
32(48%)
25(38.5%)
1(1.5%)
11(25%)
20(45%)
11(26.2%)
2(4.5%) 0.14
Unifocal
Bifocal
Multifocal
Unknown
43(71.7%)
5(8.3%)
12(20%)
6(9%)
33(76.7%)
2(4.7%)
8(18.6%)
1(2%) 0.74
Margin Radical
Irradical CIS 
Irradical invasive 
Unknown
37(56%)
10(15%)
17(26%)
2(3%)
25(57%)
8(18%)
11(25%)
0.94
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Table 2: Patients-factors, operative factors and pathological factors o f the previous excision are 
compared in 59 patients in whom a re-excision was performed.______________________________
No tumour 
n=35
Residual tumour 
n=24 p-value
Age (median) 64 50 0.030
Wire-localisation 
No wire-localisation
21(60%)
14(40%)
15(63%)
9(37%) 0.85
Diagnostic excision 
Curative intention
27(77%)
8(23%)
23(96%)
1(4%) 0.050
Tumour type CIS
Invasive
Mixed
1(3%)
11(31%)
23(66%)
7(29%)
3(13%)
14(58%) 0.0085
Histological diameter (median) 15 mm 15 mm 0.59
Weight of specimen (median) 56 gram 35 gram 0.0051
Differentiation good
moderate
poor
Unknown
9(26%)
16(46%)
10(29%)
1(4%)
8(33%)
13(54%)
2(8%) 0.033
Unifocal
Bifocal
Multifocal
Unknown
24(69%)
4(11%)
5(14%)
2(6%)
10(42%)
0
13(54%)
1(4%) 0.0026
Margin radical
irradical CIS
irradical
unknown
16(46%)
4(11%)
13(37%)
2(6%)
3(13%)
8(33%)
13(54%)
0.011
DCIS No 
(n=34) Some
extensive
13(37%)
15(43%)
7(20%)
12(50%)
2(8%)
10(42%) 0.0044
After wire localisation in 15/35 (42%) of the patients residual tumour was found, while in 9/23 
(39%) of the patients after excision of a palpable lesion residual tumour was found. If the
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excision biopsy had a diagnostic character in 32/60 (53%) of the patients’ tumour was left, if the 
biopsy was considered to be a definite excision in 4/9 (44%) patients tumour was left behind. A 
secondary procedure was more often performed in case the first excision had a diagnostic 
character (p=0.015), in case of larger tumour diameters (p=0.023), in multifocal tumours 
(p=0.0014), when the margin was positive for in situ or invasive carcinoma (p<0.05), or when 
there was an extensive in situ component (p=0.02). After correction for other factors wire- 
localisation itself was not an independent factor that predicted a reexcision (p=0.74).
Table 2 shows that residual tumour tissue was more often found in younger patients (p=0.30), 
after a diagnostic excision (p=0.05), when the primary tumour consists of DCIS only (p=0.0085), 
after a smaller primary lumpectomy (p=0.0051), with worse differentiation (p=0.33), in 
multifocal tumours (p=0.0026), when the margin was positive (p=0.011), or with an extensive 
DCIS component (p=0.0044). Wire-localisation (p=0.85) and tumour diameter (p=0.59) did not 
predict the finding of residual tumour in re-excision specimen. Lobular carcinoma in situ, a 
known factor for residual tumour, was found in only three patients.
Discussion
Since the introduction of breast cancer screening more clinically occult tumours are diagnosed. 
Wire localisation has been the gold standard for diagnosis and/or treatment of these potentially 
malignant tumours. It was not surprising to find a high number of reoperations (54%), 
considering that 75% of the procedures was with diagnostic intention. However, of the 59 
patients with an indication for a reexcision, only five were treated with a local reexcision, the 
others were treated with a simple mastectomy (12) or a modified radical mastectomy (42). The 
high number of tumours with an extensive DCIS component (17/110) or multifocal tumours 
(28/110) are partially responsible for this outcome. Furthermore elderly patients more often 
preferred an ablative procedure instead of a local re-excision with again the risk of 
incompleteness and the need for adjuvant radiation therapy. After a previous excision a 
reoperation has a less desirable cosmetic outcome, so many patients would choose for an ablative 
procedure with primary or secondary reconstruction.
DCIS is diagnosed more often with the introduction of a breast cancer-screening program, 
manifesting as non-palpable micro-calcifications. After needle localisation biopsy residual 
tumour may be found in percentages as high as 77% after thorough examination (18). Positive 
excision margins that are not treated by reexcision may lead to recurrent disease in 30% of the 
patients in a period of 10 years, even in combination with irradiation. When margins are free of 
tumour very low local recurrence rates are reached (7). It seems to be, however, difficult to excise 
the non-palpable DCIS without residual foci. In 51 % tumour-positive resection margins are 
detected after the initial resection (9). It is demonstrated in a multivariate logistic regression 
analysis that an extensive intraductal component, besides tumour grade, angioinvasion and 
lobular tumour type, is an independent predictor of local recurrence (14).
Is there still an indication for needle localised open surgical biopsy with the introduction of 
stereotactic core biopsies? Stereotactic biopsy of breast lesions can be done with the use of the 
recently developed Hand-held Mammotome (Ethicon Endosurgery, Cincinnati, OH) or other 
large-core needles with increasing accuracy, using stereotactic digital mammography to target the 
lesions. Almost any lesion can be successfully and accurately targeted and subsequently studied
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by the pathologist. These technical possibilities decrease the need of a surgical diagnostic biopsy 
in the future (13). A recent trial in the Netherlands, comparing stereotactic needle biopsy and 
open surgical biopsy, lead to a substantial decrease in the number of diagnostic operations (15). 
Morrow et al. noticed that stereotactic core needle biopsy is the diagnostic procedure of choice 
for most mammographic abnormalities. However, for patients undergoing tumourectomy without 
axillary surgery, it is an extra invasive procedure that does not facilitate obtaining negative 
margins. Therefore it will decrease the number of diagnostic operations, but at the same time 
increase the number of invasive procedures in a large group of patients (10). We therefore believe 
there will still be an important role for needle localisation biopsy in the future.
In this study the specimen weight was relatively high, compared to the internationally accepted 
30 grams for a diagnostic lumpectomy specimen. Possible explanations are that surgeons who 
perform an open surgical biopsy for diagnostic reasons keep in mind the fact that if they remove 
all tumour tissue, the patient can be spared a second operation. Indeed, in table 2 it seems that 
with a larger specimen, less tumour is left in the breast to be found after a second operation 
(p=0.0051).
We expected a tumour-positive surgical margin more often in needle localised open surgical 
biopsies than in biopsies with palpable tumours and were surprised to find that this was not the 
case. A possible explanation for this is that the localisation procedure was performed with a 
localisation needle in the centre of the tumour in a high number of the lesions, making it possible 
to remove an adequate sample, in a large percentage removing most of the tumour. Also the fact 
that specimen weights were high indicates less selective sampling in both groups, with a 
tendency to acquire more free margins in both groups. A positive surgical margin, extensive 
intraductal component, lymphatic vessel invasion and other factors have been associated with a 
high number of local recurrences (1). Although a free margin is of importance, no agreement 
exists in the literature on the margin size and radiotherapy in in situ tumours. Freedman et al. 
studied 1262 patients with stage I or II breast cancer and concluded that a close margin (<2 mm) 
has an equal or greater risk of ipsilateral breast tumour recurrence, especially following a 
reresection (5). Histological evaluation of the margins usually takes place after inking of the 
specimen (8).
Not only was there no difference in the percentage of tumour free margins, but also the 
percentage of reresections in which residual tumour was found were similar between non- 
palpable and palpable lesions in this study. In earlier studies it could be demonstrated that a free 
or close margin may be associated with residual tumour in 30% of the patients after a segmental 
resection, while 47.5% of those with a positive margin may have no residual tumour, indicating 
that the assessment of microscopic margins may be misleading (4). A large study with a follow- 
up period of eight years showed no differences in survival in women with stages I/II breast 
cancer with focally positive or focally close microscopic resection margins compared to negative 
or unknown resection margins (11). Off course these results are questionable, but they indicate 
that the definition and evaluation of resection margins is difficult. Other techniques are developed 
to prevent local cancer recurrence, like performing of peroperative touch preparation cytology 
(TPC), that has shown promising results (2). However some bias is obvious in this study and it 
would be interesting to compare conservative histology with TPC in the same specimen, instead 
of comparing TPC in the author’s institute with conservative histology in referring hospitals. 
Another possibly successful method to reduce the number of tumour-positive margins is 
ultrasound-guided lumpectomy of non-palpable breast cancers (12). Another option is to remove 
more breast tissue in a case of extensive intraductal component, as is advised by some 
investigators (14,17).
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Conclusion
In experienced hands wire localisation biopsy is not a risk factor for residual tumour after initial 
treatment of breast cancer patients, while diagnostic intentions, larger tumours, multifocal 
tumours, tumours with positive margins and tumours with an extensive in situ component all are 
risk factors for reexcision. New techniques like stereotactic biopsy change the number of 
diagnostic procedures, while other risk factors are not controlled. The role of wire localisation 
biopsies will still be important in the large group of non-palpable breast lesions.
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Summary
The purpose of this study was to evaluate the pain experience of women during mammography 
for breast cancer screening. Possible associations with personal and medical history, 
sociodemographics and/or situational factors were studied. Also was investigated whether this 
pain influenced the intention to return for future breast cancer screening.
In the Netherlands, women between 50-75 years are invited for screening every two years. A total 
of 1200 participants were asked to fill up a questionnaire.
The response rate was 79.5% (n=954) and 945 questionnaires contained adequate information for 
analyses. A total of 689 women (72.9%) described mammography as mild to severe painful. In 
this group, compared to the group that reported no pain, the following factors occurred 
significantly more often: sensitive breasts (P=0.001), family history of breast diseases (P=0.017), 
expected pain based on former mammography (P=0.001), high education (P=0.008), anxiety 
(P=0.001), breast sensitivity in last three days (P=0.001), insufficient attention of technologist 
(P=0.001). Other factors like age, hormonal status, breast size and hormone use were not 
associated with experienced pain. Thirty-two women (3.3%) indicated that they would not attend 
further screening; 25 (2.6%) reported that the pain might deter them, six women (0.6%) had other 
reasons, one woman (0.1%) was sure not to come because of severe pain.
In conclusion: a large majority of women attending breast cancer screening describes 
mammography as painful (72.9%). Factors associated with pain were described. Relatively few 
women (2.7%) indicated that the pain might deter them from future mammography. 
Recommendations are given to reduce experienced pain during screening mammography.
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Introduction
Successful reduction of breast cancer mortality depends primarily on early detection; ideally 
while the lesion is still clinically occult (1). Screening mammography is the most sensitive and 
reliable method for early detection. In order to achieve a reduction in mortality from breast 
cancer, it is essential that there is a high attendance rate of women in the population who are 
offered screening (2,3,4,5,6). A certain amount of compression of the breast is necessary to 
improve image quality, to separate overlapping structures, to reduce motion artefact, and to 
decrease the radiation dose. (7) For most women, breast compression is an uncomfortable 
experience.(8,9) Some women report severe pain and even consider not returning for a future 
screening round.(8,10) There has been growing interest in the pain experience of women 
undergoing mammography in the news media, among patient groups and in nursing 
journals. (11,12) Compared to the huge amount of breast cancer literature, relatively little has 
been written about pain during mammography in the medical journals. Because early detection 
proved to be important in reducing mortality due to breast cancer and women may not attend 
breast cancer screening because of pain, investigation of the experienced pain is desirable. This 
descriptive study was designed to determine the prevalence and intensity of pain experienced by 
women undergoing screening mammography. The presence of possible associated factors was 
investigated. The degree of alleged pain as a deterrent for further screening mammography also 
was investigated.
Patients and methods
In the Netherlands, every woman between 50 and 75 years old is invited for breast cancer 
screening with an interval of two years. During the months of September and October of 1998, 
1200 women participating in screening mammography were asked to complete a questionnaire. 
This questionnaire consisted of 25 items: 22 multiple-choice questions and three open questions. 
Information was gathered about personal and medical history factors, sociodemographics and 
situational factors. Personal and medical history factors measured were: age (< 54 years; 55-59 
years; 60-64 years; 65-69 years; > 70 years), hormonal status (premenopausal: periodical 
menstruation; menopausal: last menstruation < 1 year ago; postmenopausal: last menstruation > 1 
year ago; hysterectomy), breast size (small: AA-A; small-medium: B; medium: C; medium-large 
D; large: DD-G), quetelet index (body mass index or weight/lenght2), sensitive breasts 
(subjective recorded by ‘yes’, ‘sometimes’ or ‘no’), previous breast surgery (‘yes’ or ‘no’; if yes: 
reason for surgery?), hormone use (‘yes’ or ‘no’; if yes: kind of hormone?), family history of 
breast diseases (‘yes’ or ‘no’; if yes: malignant and/or benign?) and expected pain (expectation: 
‘no pain’, ‘little pain’, ‘moderate pain’, ‘severe pain’). Sociodemographic factors recorded were 
education (low < 6 years; low-moderate 6-10 years; moderate-high 10-12 years; high > 12 years), 
marital status (‘married’, ‘not married’, ‘divorced’, ‘widow’) and ethnic background (‘Dutch’ or 
‘other’). Situational variables measured were anxiety (subjective recorded: ‘yes’ or ‘no’), breast 
sensitivity in past three days (‘yes’ or ‘no’), last menstruation < 7 days ago (date of last 
menstruation), preceding information (‘former mammography’, ‘friends or family’, ‘doctor or 
other health worker’, ‘brochure’, ‘newspaper, journal or TV’, ‘other: namely . . . ’), attention of 
technologist (subjective recorded: ‘sufficient attention’, ‘insufficient attention’ or ‘don’t know’) 
and the number of images made. The finding of a suspect lesion on the mammogram was 
recorded. The experienced pain was rated by a 4-point pain scale (‘no pain’, ‘little pain’,
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‘moderate pain’, ‘severe pain’).(10,13) Also was asked whether the participant intended to attend 
further screening mammography when invited. The questionnaire ended with the possibility to 
write down remarks and a declaration of consent. It could be completed immediately in the 
screening unit or could be taken home and returned by mail.
All examinations were performed by one of 11 female technicians who have specialized in breast 
imaging. The women were instructed as to the nature of the mammography prior to commencing. 
Mammography was performed with a Philips mammo Diagnost BC (Philips Medical Systems, 
Hamburg, Germany) using Kodak Min-R2190 screens and Kodak Min-R2 films (Eastman Kodak 
Company, Rochester, USA).
Breast compression was achieved by use of a motorized footplate, leaving the technicians’ hands 
free for positioning the breast. The technicians compressed the breast as much as 
was required, and was tolerated, to obtain an optimum image. During the first screening round, 
oblique and craniocaudal views were obtained. During further screening rounds, which took 
place every two years, only oblique views were taken. Additional views were obtained if the 
technical adequacy of the images was not satisfactory. A radiologist judged the mammogram 
immediately and if necessary additional views were taken directly. So none of the participants 
had to return for additional views.
Table 1. Population characteristics o f945 women attending breast cancer screening.
n %
Age < 54 342 36.2
(n=945) 55-59 204 21.6
60-64 161 17.0
65-69 116 12.3
> 70 122 12.9
Education Low 232 25.5
(n=909) Low-moderate 391 43.0
Moderate-high 1 72 18.9
High 114 12.6
Marital stage Married 725 77.0
(n=941) Not married 45 4.8
Divorced 64 6.8
Widow 107 11.4
Ethnic background Dutch 913 97.0
(n=941) Other 28 3.0
Hormonal status Premenopausal 146 15.5
(n=943) Menopausal 53 5.6
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Postmenopausal 584 61.9
Hysterectomy 160 17.0
Hormone use Yes 103 10.9
(n=945) No 842 89.1
Breast size AA or A 98 10.6
(n=929) B 372 40.0
C 266 28.6
D 151 16.3
DD - G 42 4.5
Statistical analyses were performed using the Chi-square test. P-values <0.05 were considered to 
be statistically significant.
Results
A total of 954 questionnaires was returned (79.5%), nine were excluded because the question 
about experienced pain was not answered. Therefore, the analyses were performed on 945 
questionnaires. The mean age of the participants
was 59.4 years (range 49.7-75.7 years). Table 1 lists the population characteristics.
As shown in Table 2, 72.9% of the women reported experiencing pain during mammography, 
where 9.3% of these women reported severe pain.
Table 2. Experienced pain during screening mammography (n=945).
n %
No pain 256 27.1
Little pain 397 42.0
Moderate pain 204 21.6
Severe pain 88 9.3
Women with a medical history of sensitive breasts reported significantly more pain than women 
without sensitive breasts, 78.0% versus 68.7% (P=0.001). The same was valid when there was a 
family history of breast diseases, 76.2% versus 71.7% (P=0.017). Age, hormonal status, breast 
size, quetelet index, breast operations and hormone use were not associated with pain. 
Anticipation predicted the actual experienced pain among women who previously underwent 
mammography. When expectations were based on other sources, there was no association
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between actual experienced pain and expected pain. Women with a higher education reported 
significantly more often painful mammography than those with a lower education (P=0.008). The 
percentage of women with pain increased with the years of education: < 6 years 62.9%, 6-10 
years 72.9%, 10-12 years 74.4% and > 12 years 80.1%. Marital status and ethnic background 
were not associated with the reported pain.
The following situational factors were significantly associated with pain: anxiety, present among 
87.2% versus not present among 71.1% of the women (P=0.001); breast sensitivity in the past 
three days, 89.8% versus 71.4% (P=0.001); and insufficient attention given by technologist, 
88.2% versus 72.3% (P=0.001). Last menstruation < 7 days ago, preceding information, and the 
number of images that were made, were not related to pain. Also the presence of a suspect lesion 
on the mammogram was not related to pain experience.
Table 3. Factors associated with experienced pain during screening mammography.
P
Sensitive breasts 0.001
Family history of breast diseases 0.017
Expected pain (earlier mammography) 0.001
Educational level 0.008
Anxiety 0.001
Breast sensitivity during past three days 0.001
Insufficient attention of technologist 0.001
Table 3 summarizes all factors significantly related to the experienced pain.
In response to the question whether the respondent would attend future screening mammography 
when invited, 25 (2.6%) women answered that the pain might deter them. One woman (0.1%) 
indicated to be sure not to attend further mammography because of severe pain. Six women 
(0.6%) indicated that they probably would not attend because of other reasons.
Discussion
In the literature, the percentage of women reporting any pain or discomfort during the procedure 
ranges widely from 0.2% to 85%.(8,10,13,14,15) It is possible that much of the variability is due 
to the fact that both screening and clinical populations were studied. Sometimes both discomfort 
and pain were studied. Also there were many different pain measures used.(15) In the present 
study a 4-point pain scale was used. A large proportion of women (72.9%) reported having pain 
during mammography. Most often women reported little pain (42.0%), but moderate pain was 
reported by 21.6%, and 9.3% of the women reported severe pain. Other authors also found a 
relatively small subgroup of women with severe pain during mammography; range 0.9% to 
10%.(8,9,10,15,16,17) this small group of women however, could be large enough to have
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implications on a population scale when they do not attend future mammography screening. It 
would have public health implications if the women in the general population failed to attend 
mammography screening because of fear for exposure to severe pain. Therefore reports of pain 
should be taken seriously and, if possible, measures should be taken to prevent or to diminish 
experienced pain. In the present study, the pain experience of women undergoing screening 
mammography was assessed close to the time of the actual mammogram, and possible associated 
factors were investigated.
Reported pain was related to the presence of sensitive breasts (P=0.001). Other authors also have 
found an association with ‘pre-existing breast pain’ or ‘fibrocystic disease’.(13,18) It is possible 
that a high percentage of the women who indicated that they suffer from sensitive breasts have 
fibrocystic breasts. Clinical signs of fibrocystic breasts are pain and nodularity. It seems logical 
that women with fibrocystic breasts report more pain during mammographic compression, 
because cyst formation is known to produce periodic breast pain with focal tenderness on cyst 
palpation.
Against our expectation breast size was not related to pain during mammography. However, 
women with smaller breasts (size AA and A) and women with very large breasts (size > D) 
tended to perceive more severe pain. In these two groups of women, a percentage of 15.3% and 
16.7% respectively reported severe pain during mammography, compared to about 8% of the 
women with normal sized breasts. Nielsen et al.(19) also described that women with smaller 
breasts had more pain. However, no explanation was given for this finding.
In accordance with the findings of Jackson et al.(8) therapeutic hormonal manipulation with oral 
contraceptives or hormone replacement therapy did not result in more pain during 
mammography. Also no relation was found with hormonal status.
A relationship was found between a family history of maligne and/or benigne breast diseases and 
mammography pain. This association was not demonstrated before. (10,19) There was no 
difference between those women who had a family history of malignant breast disease as 
opposed to those who had a family history of benign breast conditions. The reason why the 
women with a family history of breast diseases reported more pain can be only speculative. 
However, this observation is very interesting and is worth further investigation.
The basis of the anticipation of pain was investigated: one’s own experience with mammography, 
or information from friends or family, media or health care professionals. A limitation of this 
study was that the expectations were collected after, rather than before, mammography. 
Responders may have been biased by the experience during mammography. However, only 
earlier personal experience of mammography was a significant predictor of pain (P=0.001).
An interesting finding was the fact that higher educated women reported more pain (P=0.008). 
These results support previous findings of Rutter et al.(20) and Aro et al.(10) The level of 
education may reflect better verbal skills and a higher educated woman could possibly be more 
prone to give her opinion.
Nielsen et al.(19) reported a relation between the incidence of mammography pain and racial 
background: pain levels were higher in white as opposed to African American women. Ethnic 
background did not influence pain report in the present study. However, the group of women 
with a different ethnic background was very small, only 3%.
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Compression in tender breasts is likely to produce more pain. Cockburn et al.(9) found no 
relationship between pain and breast tenderness in the previous three days. In the present study, 
we did find a significant relationship between these two variables (P=0.001).
Screening related anxiety can be affected by information delivered prior to screening and by staff 
behaviour during the process. Both anxiety (P=0.001) and insufficient attention given by the 
technologist (P=0.001) were significantly related to experienced pain. This can be explained by 
cognitive-behavioural models that view pain during mammography as the result of a continuous 
set of interactions between behaviour, biological and social-environmental influences. A change 
in one part of the system influences other parts of the system. Thus, anxiety or attention and 
support from the technician can feed back and affect experienced pain. (14) Therefore it is very 
important to train technicians in order to reduce anxiety in women attending screening.(11)
The number of images made was not associated with experienced pain. The same was true for the 
finding of a suspect lesion on the mammogram. Of course, the women did not know whether or 
not they had an abnormal mammogram at the time that they responded. So, this finding was 
unlikely to be of any influence on the pain experience.
The actual pressure applied via the mammographic plates was not measured. Therefore, it was 
not possible to obtain an objective measure to analyse a relation between compression and pain 
perception. This fact is considered as a limitation of the present study. Sullivan et al.(21) showed 
that increased force was associated with pain, however the force was also associated with breast 
thickness. A second limitation is that women who had severe pain during prior mammography 
may not have returned for a repeat exam and therefore were not subjects in this study.
The response rate of 79.5% includes 20.5% non-responders. Because this study was designed as a 
first inventarisation no attempt was made to get a higher response rate. This way we don’t have 
any information about the group of non-responders.
Also, the closing date was established before the study started: statistical analyses started the day 
after. Therefore all questionnaires we received after this date were not included (n=14).
This study and other studies conclude that pain is a common experience in women undergoing 
mammography. Although the pain was generally in the low to moderate range, a percentage of 
9.3% of the women in this study reported severe pain. Pain caused by compression necessary for 
good screen-film mammography is a potential deterrent to screening mammography programs: 
2.7% of the participants in the present study indicated that the pain might deter them from further 
examinations. As long as other, painless techniques (for example, ultrasound and Magnetic 
Resonance Imaging) are not suitable for mass screening, it is worth trying to prevent or minimize 
pain during mammography.
After studying several factors influencing pain experience, it is possible to give some 
recommendations in order to decrease pain experience during screening mammography:
In the situation that the previous mammography was very painful, or it is known that the 
participant has sensitive breasts, additional care can be taken. Suggested interventions could be 
providing more information or the use of analgesics during the procedure. Another option is 
patient control over the mammography procedure. This consists of offering women the 
possibility to control the pressure themselves. Kornguth et al.(22) showed that this measure is 
effective without compromising image quality.
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If it is possible to create a friendly screening atmosphere and to pay more attention to the 
participants, it may help to reduce experienced pain during mammography. Technicians should 
be trained in order to achieve this atmosphere in which women are less anxious.
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Abstract
Introduction. Results and experience with the treatment of non-palpable breast cancer are 
reported and related to the future of less invasive treatment of small breast cancers 
Methods. A retrospective study of 102 patients, treated between 1980 and 1993 at the University 
Hospital of Nijmegen was conducted. Most cancers were screen-detected.
Results. Tumour sizes on pathological examination proved 3 mm (SD 7.7 mm) larger than on 
mammography (p=0.0029). pT1 tumours were encountered in 77 patients (75%), pT2 tumours in 
17 patients (17%). Seventy-five patients were free of lymph node metastases, 26 patients showed 
stage pN1 (25%). Most patients had invasive ductal cancers.
Breast cancer mortality was found in two patients only. A 10-year disease free survival of 94% 
was calculated, after excluding four patients with known systemic disease (M1) at diagnosis. T1a, 
T1b, and T1c had a 10-year survival of 100%, 96%, and 96%, respectively.
Conclusion. Early detection and multimodality treatment of breast cancer have improved survival 
towards a high level. In patients with small breast cancer tumours future developments in 
treatment must be aimed at the use of less invasive techniques reducing morbidity while 
maintaining high levels of disease-free survival.
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Introduction
Breast cancer is the most frequently occurring malignancy in women, with a lifetime risk of 10­
12%. During recent decades the incidence of breast cancer has increased in Western Europe and 
the United States, while the mortality even decreased1. Part of the increase in incidence is due to 
breast cancer screening programmes 2. Mammographic screening for breast cancer makes it 
possible to detect breast cancer in a sub-clinical or non-palpable stage. The detection of these 
smaller tumours by screening shows a positive effect on survival because of decreased mortality
3 9from breast cancer . Even after a follow-up as long as 17 years there is a decrease in the 
expected rate of mortality from breast cancer after screening 10 In the Netherlands a nation-wide 
program of screening for breast cancer has been started in 1990, providing a biennial screen 
examination to women aged 50 to 69 years. This program has been implemented successfully 11.
In a recent study a more favourable prognosis is reported in pT1a-b as opposed to pT1c after a
12follow-up of 20 years .Because of the favourable prognosis in recent years several authors 
suggested a less invasive treatment in minimal breast cancers. Fein suggested that subgroups 
could be identified of patients with smaller breast cancers in which the risk of developing lymph 
node metastases was less than 10%. In these subgroups axillary lymphadenectomy could 
probably be omitted safely 13. Others, however, could not define such subgroups 14. Concerning 
local treatment Cady suggested that with the improvement of local surgical techniques adjuvant 
radiotherapy after local tumour excision might be omitted in selected cases15.
In this report we present our results and experience with non-palpable breast cancer and evaluate 
whether on the basis of these results a less invasive treatment of non-palpable breast cancer could 
be appropriate.
Methods
A retrospective evaluation was performed of 102 consecutive patients with non-palpable invasive 
breast cancer, treated at the University Hospital of Nijmegen in the period from April 1980 to 
December 1993. We define non-palpable breast cancer as clinically occult breast cancer. The 
patient mean age was 58 years (range 37-77). In 66 patients breast cancer was detected by 
population screening (65%), while the other 36 patients (35%) were detected by mammography 
outside the screening program. The general practitioners discovered these 36 clinically occult 
breast cancers in mammographies taken because of a positive family history or because of 
patients’ worries concerning breast cancer. From 1975 to 1991 a trial on screening for breast 
cancer was performed in the Nijmegen region, and in 1991 a nation wide screening program was 
started. The mammographic appearance of the 102 cancers consisted of micro-calcifications in 42 
cases (41%), and radiographically solid tumours in 60 cases (59%). Treatment consisted of a two 
step-procedure in 75 patients (74%), the first step being an excisional biopsy after needle 
localization. In the second operation the definitive treatment was performed, either a modified 
radical mastectomy or a breast saving procedure. In 18 patients (18%) three operations were 
required and in one patient (1%) four operations. The remaining seven patients (7%) were treated 
in one procedure, because a histological diagnosis of breast cancer was made already 
preoperatively. In case of incomplete resection margins of invasive tumour, reexcision was
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performed until the resection margin was free of tumour. Ductal carcinoma in situ (DCIS) in the 
resection margins was treated with either re-excision or radiotherapy, depending on the extent of 
DCIS in the margins. Re-excision was preferred in cases of poorly differentiated DCIS in the 
resection margins or when several spots of DCIS were observed within the tumour specimen. In 
this population after the diagnostic excision many patients choose a mastectomy instead of a re­
excision. Adjuvant radiotherapy to the breast area was applied in breast conserving procedures 
and in case of T3/T4 tumours or chest-wall contamination. Adjuvant radiotherapy of the axilla 
was given in case of extranodal involvement, patients with centromedially located breast cancer 
received parasternal radiotherapy. Adjuvant chemotherapy was administered depending on lymph 
node involvement and menopausal status. Over the years small changes in indications existed,
due to participation in trials. Adjuvant chemotherapy consisted of CMF (cyclophosphamide, 100 
2 2  mg/m orally on days 1 to 14; methotrexate, 40 mg/m intravenously on days 1 and 8; and 5-
fluorouracil, 600 mg/m intravenously on days 1 and 8) during 6 months. Adjuvant tamoxifen (20
mg/day for a period of 2 years) was given to postmenopausal patients depending on receptor
status of the primary tumour and lymph node involvement. Tumour staging and pathology
reports, as well as surgical and adjuvant procedures were evaluated. Outcome was determined by
recurrence free survival and overall survival.
Results
Histopathology and stage
The mean tumour size in 60 radiographically solid tumours was 14 mm (range 4-60). Tumour 
diameters measured on mammography were generally 3 mm smaller (SD 7.7 mm) than those 
reported by the pathologist. This difference was statistically significant in a univariate analysis 
(p=0.0029). Invasive ductal cancer was found in 69 (67%) patients, invasive lobular cancer in 21 
(21%) and mixed or other types in 12 (12%). There were no patients with multiple localizations 
of breast cancer in the resected tissue.
After classification by the pathologist 77 patients (75%) showed pT1 stage. The distribution of 
the different stage pT1 tumours (T1a,T1b,T1c) is given in Table 1. Seventeen patients showed a 
pT2 tumour, three patients had stage pT3 disease and five patients were classified as pT4. Of 
these five, four patients showed invasion of the skin or chest wall, in one patient the pathological 
diagnosis was made of inflammatory carcinoma.
Table 1; Postoperative lymph node status in 77 pT1 tumours, related to size.
N0 (%) N1(%) N2 (%)
p T1a (1-5 mm) 15 (94) 1 (6) 0
pT1b (6-10 mm) 23 (85) 4 (15) 0
pT1c (11-20 mm) 24 (71) 9 (26) 1 (3) p=0.05
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The mean number of lymph nodes found by the pathologists was 17 (range 7-44). 75 patients 
(74%) were staged as pN0, 26 patients (25%) as pN1 and one patient showed stage pN2. Of the 
27 patients with tumour positive lymph nodes extranodular invasive tumour growth was found in 
12 (44%). Sixteen of the 26 pN1 (62%) patients showed more than one tumour positive lymph 
node. The pN-stage in pT1 tumours was dependent on size of the tumour, with more pN1 cancers 
in tumours measuring 11-20 mm, compared with the smaller tumours (table 1). Four patients had 
known systemic disease at the time of detection of breast cancer; all four had stage pN1. These 
four were excluded in the Kaplan-Meier survival curve.
Treatment performed
Definite treatment consisted of a modified radical mastectomy in 77 patients (75%). Breast 
conserving treatment was instituted in 17 patients (17%); five patients (5%) were treated by 
simple mastectomy and three (3%) by other procedures (two lumpectomy, one quadrantectomy).
In 53 patients adjuvant radiotherapy was given: 17 as part of breast conserving treatment, 12 
because of extranodular tumour growth and in 24 because of centromedially located breast 
cancer. In 14 patients adjuvant chemotherapy was administered and in eight cases hormonal 
therapy was given. Four patients had combinations of hormonal therapy and chemotherapy.
Survival and recurrent disease
In the series no local recurrence was detected, but systemic recurrence occurred in four patients. 
All recurrences (4) were encountered in the group of patients with invasive ductal cancers, with a 
mean tumour diameter on pathological examination of 12 mm (range 10-15). No recurrences 
were observed when the tumour diameter was less than 10 mm on pathological examination. 
During the follow-up period eight patients died, two due to breast cancer and five because of 
other diseases, in one patient the cause of death was unknown. The deaths from breast cancer 
were both postmenopausal women with a pT1N1 invasive ductal carcinoma with extranodular 
tumour growth. Only one of the four women with known systemic disease by the time of the 
operation died of breast cancer. Two others are still alive after 5 and 11 years while one woman 
died after 3 years from a heart attack.
Recurrence free survival of the whole series is given in Figure 1. Five, 10 and 12 years recurrence 
free survival is 97%, 94% and 88%, respectively. Separate analysis for different stage T1 tumours 
(T1a,T1b,T1c) did not show any significant difference in recurrence free survival between the 
different stages.
Comparison of the 10-year survival in patients that presented with micro-calcifications and 
patients that presented with radiologically solid tumours also did not show a significant 
difference.
Discussion
More than 10 years ago the initial experience with a large series of clinically occult invasive and 
non-invasive breast tumours after excisional biopsy was presented 16 At that time the prognosis 
of clinically occult breast cancer was already extremely good and has improved only slightly over 
the years. In that study also in situ carcinomas were included and a 10-years-survival of 90% in
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patients with tumours of 6-10 mm was found. After updating and extending the series, we have
excluded the DCIS tumours. In the present series a 10 years recurrence free survival was
observed of 94%. This figure is in concordance to data from a recent study in which a 5 years
12survival rate of 97% for pT1N0M0 disease was observed . In this study however, a significant 
difference in survival between the different T1 stages was found. After 20 years of follow up the 
survival rate for pT1a-b tumours was 92%, while in pT1c tumours a 20-year survival rate was 
observed of 75%. In our series we could not demonstrate this difference.
Figure 1; Kaplan-Meier recurrence free survival curve in 98 patients, treated fo r  non-palpable 
breast cancer. Four patients were excluded due to systemic disease at the time o f  initial 
treatment. N=number o f patients in study.
N= 98 97/91 87 35 24-23 10
Already in 1971 Gallagher and Martin expressed that no major upward change in survival could 
be expected owing to improvement of surgical treatment of breast cancer. They suggested that a 
less radical approach might produce comparable results. In this regard a distinction should be 
made between local treatment of the tumour and the approach to axillary lymph node dissection
• • 17as separate entities .
Concerning local treatment of the tumour, it is surprising that in the present series a high
proportion of women was treated by modified radical mastectomy. This is even more so since
tumours were generally small while multifocal tumours were not encountered. Large studies gave
proof that treatment of breast cancer patients in stages I and II with breast conservation have
18survival rates equal to patients treated with modified radical mastectomy . So, in our series 
many patients received over-treatment according to the definite pathology report. Our results
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confirm, however, that in patients with small breast cancers multifocal tumours are rare. These 
results not only show that local treatment of small breast cancers is rational, but they also indicate 
that there may be a place for even a minimal invasive approach in patients with small breast 
cancers.
In this regard the further development of stereotactic techniques seems promising. With the use 
of stereotactic biopsy techniques it is possible to perform a one-stage procedure in many patients 
with non-palpable breast cancer, eliminating the need for further treatment by excision of the 
tumour area. For example, in a recent study it was demonstrated that patients who underwent a 
stereotactic excisional biopsy showed a rate of positive tumour margin and residual tumour 
comparable to patients who received conventional excisional biopsy 19. These data show that in 
appropriately selected patients the use of these less invasive techniques for the treatment of small 
breast cancers seems within reach.
With a tendency towards minimal invasive treatment the role of axillary lymphadenectomy in 
small breast cancers has extensively been discussed. It has been proposed that tumour factors 
could indicate which patients with T1a and T1b tumours have a high risk of tumour recurrence or 
lymph node metastases. Identifying these patients might facilitate appropriate management,
omitting routine axillary lymphadenectomy when the risk of lymph node metastases is minimal
20. In a study by Leitner nuclear grade and lymphatic vessel invasion were used to identify the
risk of tumour recurrence. The combination of poor nuclear grade and presence of lymph vessel
invasion identified a small subset of patients with T1a and T1b cancers with a significant risk of
21relapse that warrants consideration of adjuvant systemic therapy . Other studies indicated that
22morphometric features might be an important prognostic indicator . Patients with grade I (well
differentiated) pT1a-b breast cancer, with a low mitotic count and lack of tumour necrosis, may be
12spared adjuvant systemic therapy, because of their excellent long term outcome .
In our series 15 of the 77 patients (19%) with pT1 tumours showed tumour positive lymph nodes, 
which means that omitting axillary staging by lymphadenectomy would have resulted in a 
significant percentage of patients with understaging. Even in pT1a and pT1b tumours as many as 
6% and 15% of the patients showed tumour positive nodes. These figures are in concordance to a 
recent study in which tumour positive lymph nodes were found in 10% and 15% of patients with 
pT1a and pT1b 14 Moreover several studies report that omitting an axillary lymphadenectomy in 
pT1a and pT1b patients is associated with significant impairment of overall and disease-free 
survival 23,24 A large retrospective evaluation using data of the National Cancer Data Base from 
547,847 women, showed that the 10-years survival was significantly worse when axillary
25lymphadenectomy was omitted in stage I breast cancer . So also in small breast cancers axillary 
staging is of clinical significance.
However, with the recent introduction of the sentinel node concept minimal invasive axillary 
staging becomes possible. Sufficient evidence exists that examination of the sentinel node can 
replace complete lymphadenectomy as staging procedure. A review of the literature shows that 
the sentinel node can be found in more than 90% of the patients, and that the false-negative rate is 
below 5% 26 By performing serial sectioning of the sentinel node and immuno-histological 
staining micrometastases can be demonstrated, that would not have been found otherwise. 
Especially in patients with small breast tumours, in which the incidence of tumour positive lymph 
nodes is relatively low, the sentinel node biopsy is a significant step forward by avoiding 
unnecessary axillary lymph node clearance.
Early detection and multidisciplinary treatment of breast cancer have improved survival towards 
a high level. In the future we cannot expect better treatment modalities to improve this level of
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treatment results even more. Because of screening programs many breast cancers will be detected 
in an earlier stage of disease. The standard treatment options carry a significant morbidity and 
often have cosmetically unsatisfactory results. For these small breast cancers there seems a 
future for less invasive treatment strategies.
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Chapter 9
Detection of 
breast cancer 
after biopsy 
for false-positive 
screening mammography. 
An increased risk?
False positive breast cancer screening results
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Abstract
Introduction: After false-positive screening for breast cancer, women are still at risk for 
developing breast cancer. In this study the incidence of breast cancer in a group of women who 
had a false-positive outcome is compared with the expected breast cancer incidence.
Methods: Follow-up data of 188 women (mean age 58 years) with a false positive screening 
result were collected and analysed for breast cancer development. The mean length of follow-up 
in the study was 7.4 years. The occurrence of breast cancer was compared to the expected 
incidence of breast cancer in an age-matched control population using figures from the local 
cancer registration.
Results: The occurrence of breast cancer in the study population (n=7) was not significantly 
different from the expected incidence of breast cancer in the age-matched control group (n=5). 
Conclusion: There is no relationship between false-positive findings during breast cancer 
screening and later development of breast cancer. Patients who do not have an increased risk of 
developing breast cancer (due to family history) should not be followed-up clinically, but should 
be returned to the screening programme.
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Introduction
Screening for breast cancer in women betwee1n,2 ,t3h,4e,5 ,a6,g7e of 50 and 70 years is an effective method 
to decrease the mortality rate of the disease , , , , , , . In women with a suspect mammography 
during screening the malignancy rate varies between 5 and 70%, depending on training and 
experience of the screening team . In a section of the referred women with an abnormal 
screening mammography in one single direction no lesion will be found on a bi-directional in­
hospital mammography or with ultrasound, while another section of the women will undergo a 
biopsy for a benign lesion or a malignancy 9.On the other hand, small malignant tumours may be 
missed during screening due to technical or observational failure. These failures may lead to 
interval carcinomas afterwards. Moreover, interval carcinomas may occur due to failure in biopsy 
technique leaving the suspected area in situ or by misinterpreting histopathology of the tissue 
removed 10. Already in 1968, Potter reported a five time higher risk of breast cancer than average 
in women after excision of a benign breast lump n . For this reason several authors suggest close 
follow-up after excisional biopsies for benign breast lesions.
In this study we evaluated the number of operative procedures for malignancies or benign 
abnormalities during follow-up of patients initially operated for benign breast lesions detected 
during screening, or not operated after a false-positive screening. According to literature we 
expected a higher incidence of breast cancer in patients who previously had a false-positive 
screening result compared to women attending the screening programme without previous false- 
positive screening.
Patients and methods
Between 1985 and 1996, 188 women were referred from screening in the Nijmegen region
(150,000 inhabitants) to one of the two hospitals in Nijmegen because of a lesion on screening
mammography that turned out to be benign after excision in 101 patients (54%), or could not be
reproduced by the radiologist with bi-directional in-hospital mammography and/or ultrasound in
87 patients (46%). In Nijmegen, a pilot-study for the population-screening programme invited
around 13,500 women aged between 40 and 79 years to attend for bi-annual mammography,
12which consists of single view films of each breast in the medio-lateral oblique projection . 
During the first screening round, after previous breast surgery and in mastopathic breasts, a bi­
directional mammography was made.
After referral and subsequent diagnostic procedures the mean follow-up period in this study was 
7.4 years. Information concerning the follow-up period was gathered using patient files, written 
information from the general practitioners and information from SVOKON (‘Stichting Vroege 
Opsporing Kanker Oost-Nederland’, an organization concerned with early detection of breast 
cancer in the east of The Netherlands). All breast-related pathology that developed after previous 
false-positive screening was compared with the information concerning location and pathology of 
the previously screened abnormality. Pathological diagnoses both initially and following 
resections were related to the occurrence of breast cancer. The incidence of breast cancer was 
compared with the incidence of breast cancer in an age-matched group from the same region. 
This incidence was calculated from figures obtained from SVOKON.
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Results
The median age of the 188 women at referral was 57 years (41-79 years). In the follow-up period 
11 of 188 women (6%) died, none because of breast cancer. Sixteen women (9%) had previous 
surgery for benign breast lesions, while three (2%) had previous reconstructive surgery of the 
breasts. The family history for breast cancer was positive in 45 women (24%), of whom in two 
(1%) an indication for genetic counselling existed, using the criteria from the Department of 
Clinical Genetics, University Medical Center Nijmegen. Most patients were referred
Table 1: Indications fo r  referral o f  patients with suspected mammography during screening with 
confirmed benign lesions after subsequent diagnostic procedures (n = 188)
Radiology Screening (%) Hospital (%)
mammography mammography
N=188 N=188
Density 96 (51) 67 (36)
Micro-calcification 69 (37) 63 (34)
Disturbed pattern 11 (6) 3 (1.5)
Microcalc. with density 10 (5) 17 (9)
Asymmetrical breasts 1 (0.5) -
Other 1 (0.5) 3 (1.5)
No abnormalities - 35 (19)
because of densities (n=96, 51%), or microcalcifications (n=69, 37%) found during screening 
(table 1). Most lesions were found in the lateral upper quadrant (49%) or centrally in the breast 
(31%) (fig. 1).
Of the 188 women referred for abnormal mammography, 38 women (20%) had a palpable mass, 
while 150 women (80%) had no palpable abnormalities. In 87 (46%) patients the suspect lesion 
observed on screening mammography could not be confirmed by ultrasound and/or in-hospital 
mammography performed in two directions. In 35 out of these 87 patients no lesion was found on 
in-hospital mammography, in 52 cases the observed abnormality was qualified as not suspect. All 
these patients were advised to return to the screening programme after a follow-up period of 3 
months that ended after another bi-directional in-hospital mammography. In the other 101 
patients a benign lesion was excised during an excisional biopsy. Wire-localization was used in 
83 of the 101 patients (82%), of which 63 had an impalpable lesion. The pathological diagnoses 
of the lesions excised are given in table 2.
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Figure 1: Location o f benign breast lesions, detected at breast cancer screening in 188 patients
Table 2: Pathological diagnoses o f  101 excisional biopsies fo r  suspicious lesions detected by 
screening mammography.
Pathology Number (%)*
Cyst 33 (16)
Fibrosis 30 (15)
Adenosis 26 (13)
Atypical ductal hyperplasia 17 (8)
Fibro-adenoma 15 (8)
Scar lesion 10 (5)
Atypical lobular hyperplasia 8 (4)
Normal tissue 7 (4)
Papilloma 2 (1)
Other (benign calcifications) 53 (26)
*Several specimens showed composed lesions with more than one pathological diagnosis.
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Using the figures from SVOKON the expected prevalence in a group of 188 women with the 
same age and length of follow-up would be five new cases of breast cancer. During the follow-up 
period seven patients developed breast cancer; the characteristics of these patients are shown in 
table 3. The difference between expected and actual prevalence of breast cancer is not significant 
(p=0.4).
The median interval period before development of breast cancer was 5.2 years (2.9-8.2). Breast 
cancer was found significantly more often (p=0.05) in patients who had no excisional biopsy (six 
out of 87, 7%) than in patients who had an excisional biopsy (1 of 101, 1%). In four of these 
seven patients, however, the tumour developed at a location different from that of the false- 
positive lesion. This fact and the long median interval before development of breast cancer (5.2 
years) indicate that the above-mentioned statistical difference is of no clinical value.
During the follow-up period only six patients were operated on for benign indications: fibro­
adenoma (one), cystic disease (two) and no abnormality (three).
Table 3: Characteristics o f  7 patients developing breast cancer after previous false-positive 
screening fo r  breast cancer.
Patient Age 
(years)
Interval
(years)
Radiological
diagnosis
(screening)
1 58 5,4 density
2 66 4,1 cyst
3 51 8,2 pattern disturbed
4 66 5,0 cyst
5 65 2,9 cyst
6 76 4,9 density
7 49 5,7 density
Discussion
The 3.7% prevalence of breast cancer found during follow-up was not statistically different from 
the expected prevalence in 188 women of the same age in the same region with the same length 
of follow-up. These data demonstrate not only the reliability of our approach, but also 
demonstrate that there is no proof that the incidence of breast cancer is increased in patients with 
a false-positive screening result, indicating a missed cancer. Moreover, benign lesions in screened 
women seem not to lead to an increased incidence of breast cancer.
The implementation of a countrywide mammography screening programme leads to a 
considerable increase in the number of non-palpable and therefore clinically occult breast
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lesions8. These lesions have to be evaluated predominantly by surgical lumpectomy after wire- 
localization or stereotactic core biopsy. In patients with almost certain benign lesions on 
mammography, mammographic surveillance may be a viable option open to radiologists with
13adequate training in mammography in order to lower the rate of negative biopsies . However, 
even in a population of patients with probably benign lesions, 0.5%- 1.6% of the patients will 
develop breast cancer in a follow-up period of 2 - 3 years 14 Hence, in most cases biopsy of the 
suspected lesion remains the treatment of choice. The consequences on the healthcare system, 
however, are considerable.
During the first five screening rounds in our region in the period 1975-1984, 450 women were 
treated for a benign lesion. If this figure was representative for The Netherlands 45,000 women 
would have had false-positive results in this period 9. Other studies indicate a cumulative 10-year 
risk of false-positive screening of 32% 15. In the present study, with an identical time period, 
fewer women from the same population area were treated for false-positive mammographies. 
This significant decrease in false-positive mammographies can be explained by the increased 
experience of the radiologists analysing the mammographies.
In this study we used the wire-localized biopsy technique, an approach that has proved highly 
reliable and is previously described by Tinnemans 16 and Proudfoot 17
After breast-conserving treatment for breast cancer, scar formation is a well-known problem, 
causing diagnostic difficulties during subsequent mammographies because of the occurrence of 
fibrotic lesions and microcalcifications 18,19 These benign calcifications may include suture 
calcifications, necrotic tissue, and fat necrosis 19. Breast surgery and irradiation of the breast both
compromise the vascular supply of the breast tissue, inducing pronounced scarring and micro-
20calcifications .In a study of the management of these micro-calcifications a follow-up
mammography was recommended when these micro-calcifications develop within 3 years after
20treatment .In a Medline search, using Pubmed on the Internet, no relevant literature could be 
found in the last 10 years about the formation of scar tissue after lumpectomy alone, without 
post-operative radiotherapy. In our series with a mean follow-up period of 7.4 years only 6 
patients (3.2%) were operated for a benign lesion, none of them because of scar tissue or 
microcalcifications after previous surgery. Therefore, scar tissue formation after local excision 
seems not to be a serious problem for further diagnostics.
Outpatient follow-up of women after a false-positive screening result will only lead to increased 
healthcare costs. Completely omitting screening after treatment for benign breast lesions, as 
suggested by Wakefield and Powis 21, seems hazardous, because in our population we found that 
in women with a false-positive screening result the risk of developing breast cancer was identical 
to that of a control population of age-matched women who are in a screening program.
It is concluded that after adequate excision biopsy as confirmed by specimen radiography, short- 
interval follow-up mammography is unnecessary to assess for residual abnormalities. Moreover, 
women who have had excision biopsy for a benign lesion do not have an increased risk to 
develop breast cancer compared to age-matched controls. Therefore women who have had a 
false-positive screening result should be returned to the screening program as soon as possible.
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Abstract
Introduction
Breast cancer screening leads to detection of the disease, but will also lead to detection and 
treatment of benign breast lesions. These lesions are called false-positive lesions. The follow-up 
of patients with false-positive lesions in a screening region is registered, in order to evaluate the 
eventual fate of these women.
Patients and methods
We evaluated retrospectively the follow-up of 188 women with screen detected suspect lesions 
that turned out to be benign after radiological or clinical evaluation. We used hospital patients 
files, information from the regional organisation responsible for breast cancer screening 
(SVOKON), and information from general practitioners Also the development of breast cancer 
during the follow-up period was registered.
Results
The median follow-up period of the whole group was 7.4 years (mean 7.7 years). After 
establishing the false positive diagnosis the mean length of the follow-up by the hospital was 522 
days (SD 859), the median follow-up of the hospital 150 days. It was found that 113 women 
(62%) were still in any form of follow-up, of whom in 78% the follow-up was performed at 
SVOKON, 12% at the hospital and 10% by the general practitioner. Thirty-six women (20%) did 
not participate in any follow up schedule, while 13 women were discharged from follow-up 
because of age. Thirty-six women were lost to follow-up.
Conclusion
Follow-up after false-positive screening results can best be done by the screening organisation, 
since there is no indication for other means of follow-up of patients after false-positive screening 
results. Too many patients are lost to follow-up, because none of the institutions involved has 
insight in the follow-up performed by others.
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Introduction
In the Netherlands since 1989 a biannual screening program for breast cancer is implemented, in 
order to reduce the mortality from breast cancer. Dutch trials such as the DOM-project and the 
study in the Nijmegen test-region showed a decrease in the mortality from breast cancer (1,2,3). 
Some radiologically suspect lesions that are removed as excisional biopsy turn out to be benign. 
These lesions are defined as false-positive results of the breast cancer screening program. In the 
Nijmegen area 450 of these benign lesions were detected during the first five screening rounds in 
the period 1975-1984. Extrapolation of this figure would have led to 45,000 benign lesions 
removed in the Netherlands during this period (4). Excision of benign lesions can lead to severe 
anxiety in patients and increased costs of health care (5). Follow-up of these lesions by 
mammography as suggested by some authors will overstretch a surgical outclinic and induce 
increased health care costs as well (6,7,8). We evaluated follow-up methods in patients with a 
false-positive screening result in order to determine which method of follow-up is most useful.
Patients and methods
All 188 patients in the period from 1985 to 1996, referred to one of the two Nijmegen hospitals 
after breast cancer screening, in whom the evaluation revealed a benign lesion were studied 
retrospectively. The median age of the women was 57 years (41-79), by the time of the first visit. 
After bi-directional mammography and optional additional ultrasound evaluation in 87 women 
(46%) further evaluation was not necessary. In the remaining 101 patients an excision biopsy was 
performed of the radiologically suspect lesion in 83 (82%) after wire-localization, and in 18 
(18%) without wire-localization. The location and period of follow-up were recorded using 
patient-files from the two hospitals, and written information from general practitioners. 
Additional information was obtained from SVOKON (‘Stichting Vroege Opsporing Kanker Oost 
Nederland’, an organisation responsible for early detection of (breast) cancer in the region).
Results
The median follow-up of the whole group was 7.4 years (mean 7.7 years). In only six patients 
there was insufficient information to determine how follow-up was performed. Ten of the 
remaining 182 women (5%) were lost to follow-up because they died of causes other than breast 
cancer. Seven women (4%) developed breast cancer and were removed from the follow up, one 
of them died and three women were lost to follow-up because they moved to another region. At 
the time of the evaluation 113 women (62%) were still under follow-up while the remaining 49 
(27%) were discharged because of old age (13) or just because none of the above mentioned 
organisations or institutions performed the follow-up (36 women, 20%).
Of the 113 patients, 88 (78%) were still in the breast cancer screening program (SVOKON), 14 
patients (12%) were under follow-up by the hospital and 11 patients (10%) by the general 
practitioner. Surprisingly seven patients who were still in the screening program also consulted 
the general practitioner regularly for their breasts, including mammographic evaluation. It is 
therefore possible that mammographies were made by SVOKON as well as on request of the 
general practitioner.
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The period that women were seen by specialists on an outpatient basis after a previous false- 
positive screening mammography should ideally be until the first mammography after three 
months. However, we found that the average length of follow-up of outpatients was 522 days, 
with a standard deviation of 859 days and a median length of follow-up of 150 days, indicating 
that most patients are kept longer than three months and that some patients are kept for years. The 
patients that were kept in outpatient follow-up for longer than three months, were the 14 patients 
mentioned before who had their follow-up performed in the hospital.
The incidence of breast cancer in the study population (n=7) was not significantly different from 
the expected incidence of breast cancer in the age-matched control group from the same 
population (n=5).
Discussion
Although all patients with a false-positive result from screening mammography can be safely 
returned to the screening program, as has been previously concluded from a study in the same 
population (9), this study shows that many patients are controlled for a long period at the hospital 
where the first consultation or diagnostic lumpectomy was performed. Some patients are 
controlled for more than ten years, but a median follow-up of 150 days indicates that the follow- 
up is too long altogether, increasing costs for health care and imposing an extra workload on 
already overstretched schedules.
Most patients are returned to the screening program, but a relatively large number of patients 
(36/182 patients, 20%) do not have any form of radiological breast control. The hospital patients’ 
files indicated that these patients were sent back to the screening program, but no information 
about further screening results could be found by the screening organisation. Also the general 
practitioners thought that these patients attended the screening program. What is the reason that 
these patients no longer attented the screening program after a false positive screening result? It 
may be the distress of a possible confrontation with a suspect lesion and the consequent 
consultation of the surgeon and subsequent investigations, including excisional biopsies. Do 
these patients receive beforehand adequate information about the implications of the finding of a 
suspect lesion? Is admittance to the hospital always necessary or is it possible to perform less 
invasive biopsy procedures on outpatient basis? If we really want that many women attend the 
breast cancer screening program we have to think over these questions. For a good result of a 
screening program, participation from a high percentage of the target population is necessary. It 
is therefore important to keep the number of false-positive screening results as low as possible, 
without decreasing the sensitivity of the screening process for breast cancers.
Some patients were controlled by the general practitioner. Advantage of this follow-up is that 
mammography can be combined with physical examination (10). A disadvantage is that these 
women are kept out of the screening program and are lost to follow-up when the general 
practitioner stops controlling them. The fact that some patients were controlled by the general 
practitioner as well as by the screening program indicates that the general practitioners are not 
always informed about participation of their patients into the screening program. There are 
indications, however, that control by the general practitioner is preferable to that of the specialist. 
In a randomised controlled economic evaluation of the costs of follow-up for breast cancer it was 
found that the follow-up by primary care was less expensive and as good as follow-up by 
specialists (11).
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Flow chart: the method offollow-up o f 188 patients with a false-positive result o f  the breast 
cancer screening program, after a median period o f  7.4 years.
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Died of other 
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Moved to 
other region 
3
No follow-up 
6
Breast cancer
diagnosed
7
113
Follow-up:
• 88; SVOKON screening program
• 14; hospital (out-patients)
• 11; general practitioner
106
R.P.R. Groenendijk, 2003
In the follow-up period of 7.7 years 7 patients developed breast cancer. In a group of women 
from the same population, with the same age, and the same length of follow-up, an expected 
prevalence of 5 was calculated, using figures of the screening organisation. This figure is not 
significantly different from the actual prevalence found. Continuing follow-up on an outpatient 
basis is therefore not indicated (Groenendijk, 2001).
We conclude that after a false-positive screening result, either with or without biopsy, and an 
initial follow-up mammography after three months, patients should be returned to the screening 
program for a biannually screening mammography.
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Summary
Chapter 1;
Chapter 1 is an introduction to the breast cancer screening programs. Several topics on breast 
cancer screening are discussed, such as;
• Epidemiology of breast cancer
• Primary and secondary prevention
• Screening in younger women
• Screening in older women
• Interval between screening rounds
• Diagnostic protocol
• Needle biopsies
• Breast MRI
• Therapeutic protocol
• False positive results
• Interval breast cancers
• Minimal surgical approach for breast cancer
Chapter 2;
In chapter 2 the several objectives of the different studies are given.
Chapter 3;
We know that screening for breast cancer leads to detection of smaller tumours with less lymph 
node metastases. In the theory of length-time bias a screen detected tumour could have a less 
aggressive biological behaviour. The aim of this study was to investigate whether there is 
difference in biological behaviour as determined by the MAI between screen and non-screen 
detected breast cancers, and to evaluate the prognostic value of the MAI for recurrence free 
survival, after adjusting for other prognostic factors.
A retrospective study was performed on 387 patients with breast cancer, treated at the University 
Medical Centre Nijmegen between January 1992 and September 1997. Ninety patients had screen 
detected breast cancer, 297 patients had breast cancers detected outside the screening program.
The MAI, other prognostic factors, and recurrence-free survival were determined.
The MAI was twice as high in non-screen detected tumours as in screen-detected tumours, even 
after correction for stage. The MAI correlated well with other tumour characteristics. The MAI 
proved to be an independent prognostic factor for recurrence-free survival.
Favourable outcome in screen detected breast cancer is not entirely caused by detecting cancer in 
early stages: quantitative features such as the MAI indicate a less malignant character of screen 
detected breast cancer.
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Chapter 4;
Since the breast cancer-screening program has started, many cancers are detected due to this 
program. However, tumours are also detected in between two mammographic screening rounds, 
after a previous negative screening result. These interval tumours have an intermediate outcome. 
The Mitotic Activity Index (MAI) is a strong prognostic factor for disease free survival in breast 
cancer. In chapter 4 it was shown that the MAI is lower in screen-detected tumours, indicating a 
less aggressive biological behaviour in this group. In the study described in this chapter the MAI 
is compared between screen-detected, interval and symptomatic breast cancers.
Between 1991 and 1999, the MAI was determined in 581 breast cancers, 160 (28%) detected by 
screening, 66 (11%) interval carcinomas, and 355 (61%) symptomatic breast cancers. Besides 
MAI other prognostic factors were registered.
The interval group had a significantly higher median MAI (17-18, range 1-134) than the screen 
detected group (7-8, range 0-94, p<0.0001), but there was no difference with the symptomatic 
group (MAI 15, range 0-149, p=0.92). Interval cancers had an intermediate outcome for other 
prognostic factors, compared to screen detected and symptomatic cancers.
We could conclude that interval breast cancers have a higher MAI than screen detected breast 
cancers, indicating a more aggressive biological behaviour. The MAI however, is not higher in 
the interval group than in the symptomatic group.
Chapter 5;
It is the goal of the study described in this chapter to investigate whether breast cancer in patients 
with a positive family history is detected at an earlier stage with more favourable prognostic 
indices than breast cancer in patients without a positive family history. In 481 patients tumour 
size, tumour type, lymph vessel invasion, blood vessel invasion, receptor state, lymphatic spread, 
MAI and survival were measured and compared, according to their family history.
No difference was found between patients without a family history, patients with first-degree 
relatives or patients with second-degree relatives with breast cancer. Tumours were detected in 
the same stages and prognostic factors, MAI and survival were similar in all groups.
At this moment a positive family history of breast cancer does not lead to earlier detection of 
breast cancer or a better survival.
Chapter 6;
Breast cancer screening theoretically leads to more diagnostic lumpectomies. In this chapter it is 
investigated which factors may contribute to tumour-positive margins in patients who undergo a 
lumpectomy as the initial stage in the treatment of breast cancer.
A descriptive, prospective study was performed in the IJsselland Hospital in the Netherlands 
between January 1998 and December 1999, in which 110 women were included with a median 
age of 62 years (range 26-88). The indications for reoperation and the pathology reports of 
sampled specimen were studied. We analysed the numbers of samples with tumour-positive 
margins, the number of reoperations, and the frequency of residual tumour in the reexcision 
specimen.
Risk factors for more frequent reexcisions that could be identified were: Diagnostic intentions 
(p=0.015), larger tumours (p=0.023), multifocal tumours (p=0.0014), tumours with positive
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margins (p=p<0.05) and tumours with an extensive in situ component (p=0.02). Residual tumour 
was more often found in younger patients (p=0.03), after a diagnostic excision (p=0.05), when 
the primary tumour consists of DCIS only (p=0.0085), after a smaller primary lumpectomy 
(p=0.0051), in tumours with poor differentiation (p=0.033), in multifocal tumours (p=0.0026), 
after a positive margin (p=0.011), or with an extensive in situ component (p=0.0044).
We concluded that many risk factors for reoperation and residual tumour after lumpectomy for 
breast cancer can be identified, however wire localisation biopsy is not one of them.
Chapter 7;
The purpose of this study was to evaluate the pain experienced by women during mammography 
for breast cancer screening. Possible associations with personal and medical history, 
sociodemographics and/or situational factors were studied. Also we studied whether this pain 
influenced the intention to return for future breast cancer screening examinations.
In the Netherlands, women between 50-75 years are invited for screening every two years. A total 
of 1200 participants were asked to fill up a questionnaire.
The response rate was 79.5% (n=954) and 945 questionnaires contained adequate information for 
analyses. A total of 689 women (72.9%) described mammography as mild to severe painful. In 
this group, compared to the group that reported no pain, the following factors occurred 
significantly more often: sensitive breasts (P=0.001), family history of breast diseases (P=0.017), 
expected pain based on former mammography (P=0.001), high education (P=0.008), anxiety 
(P=0.001), breast sensitivity in last three days (P=0.001), insufficient attention of technologist 
(P=0.001). Other factors like age, hormonal status, breast size and hormone use were not 
associated with experienced pain. Thirty-two women (3.3%) indicated that they would not attend 
further screening; 25 (2.6%) reported that the pain might deter them; six women (0.6%) had other 
reasons for not attending the screen mammography, one woman (0.1%) was sure not to come 
because of severe pain.
In conclusion: a large majority of women attending breast cancer screening describes 
mammography as painful (72.9%). Factors associated with pain were described. Relatively few 
women (2.7%) indicated that the pain might deter them from future mammography. 
Recommendations are given to reduce experienced pain during screening mammography.
Chapter 8;
Results and experience with the treatment of non-palpable breast cancer were studied and related 
to the future of less invasive treatment of small breast cancers.
A retrospective study of 102 patients, treated between 1980 and 1993 at the University Medical 
Centre Nijmegen was conducted. Most cancers were screen-detected.
Tumour sizes on pathological examination proved 3 mm (SD 7.7 mm) larger than on 
mammography (p=0.0029). pT1 tumours were encountered in 77 patients (75%), pT2 tumours in 
17 patients (17%). Seventy-five patients were free of lymph node metastases, 26 patients showed 
stage pN1 (25%). Most patients had invasive ductal cancers.
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Breast cancer mortality was found in two patients only. A 10-year disease free survival of 94% 
was calculated, after excluding four patients with known systemic disease (M1) at diagnosis. T1a, 
T1b, and T1c had a 10-year survival of 100%, 96%, and 96%, respectively.
In the population we studied early detection and multimodality treatment of breast cancer resulted 
in a high 10-year survival rate. In patients with small breast cancer tumours future developments 
in treatment should be aimed at the use of less invasive techniques reducing morbidity while 
maintaining high levels of disease-free survival.
Chapter 9;
After false-positive screening for breast cancer, women are still at risk for developing breast 
cancer. In this study the incidence of breast cancer in a group of women who had a false-positive 
outcome is compared with the expected breast cancer incidence.
Follow-up data of 188 women (mean age 58 years) with a false positive screening result were 
collected and analysed for breast cancer development. The mean length of follow-up in the study 
was 7.4 years. The occurrence of breast cancer was compared to the expected incidence of breast 
cancer in an age-matched control population using figures from the local cancer registration.
We found that the occurrence of breast cancer in the study population (n=7) was not significantly 
different from the expected incidence of breast cancer in the age-matched control group (n=5) 
and concluded that there is no relationship between false-positive findings during breast cancer 
screening and later development of breast cancer. Patients who do not have an increased risk of 
developing breast cancer for other reasons should not be followed-up clinically, but should be 
returned to the screening program.
Chapter 10;
Breast cancer screening leads to detection and treatment of benign breast lesions. The follow-up 
of patients with these lesions in a screening region is registered, in order to evaluated the 
possibilities for omitting outpatient follow-up.
In two hospitals in Nijmegen follow-up methods using patient’s files, information from the 
screening organisation (SVOKON), and information from general practitioners were evaluated in 
188 women. The development of breast cancer or other, benign lesions during the follow-up was 
registered.
The study had an average length of follow-up of 7.7 years. While the mean length of outpatient 
follow-up was 522 days (SD 859), the median length of outpatient follow-up was 150 days. In 
113 women (62%) follow-up was performed until the end of study registration (august 1999). 
Forty-nine women were no longer in follow up at that time because of old age (13) or they were 
just lost to follow up (36). Of the 113 women who were still under follow up, follow up was 
performed in 78% at SVOKON, in 12% at the hospital and in10% by the general practitioner. 
Many patients are lost to follow-up, because one institution has no insight in the follow-up 
performed by others. Therefore follow-up after false-positive screening results can best be done 
by the screening organisation, since there is no indication for follow-up of outpatients after false- 
positive screening results.
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Recommendations
Since screen detected breast cancers have a better outcome with a less aggresive biological 
behaviour, participating in a screening program seems highly recommandable from this point of 
view.
Interval tumours should not be considered as very aggresive forms of breast cancer and the 
patients with an interval tumour should receive the standard breast cancer treatment.
A positive family history is not enough of a warning for many woman, practitioners and surgeons 
to perform screening. We should pay more attention to risk factors, in order to achieve earlier 
detection and improve the survival.
It seems difficult to achieve tumour-free margins after diagnostic procedures, especially with 
non-palpable tumours. Wire localisation can still be used in those cases, without much additional 
risk for tumour positive margins.
Pain, experienced during mammography by women attending a screening round, will deter them 
from participating in future screening rounds. For this reason or when it is known that the 
participant has sensitive breasts, additional care can be used. Suggested interventions could be 
providing more information or removing anxiety during the procedure. Another option is patient 
control over the mammography procedure. This consists of offering women the possibility to 
control the pressure themselves.
Future developments in breast cancer treatment of selected groups of patients should be aimed at 
less invasive techniques, since the survival in those selected groups is already very high. 
Reducing morbidity of breast cancer treatment is a promissing challenge in future treatment 
regimens.
It seems a safe procedure to refer patients back to the screening program after a false positive 
result in the screening program, whether they were operated on or not, under the condition that a 
completion mammography is made several months after the treatment. Besides, to prevent many 
women to be lost to follow-up because of follow-up being scattered over many institutions, it is 
recommendable as well to send all false-positively judged patients back to the screening 
organisation. For women who have a higher risk to develop breast cancer an exception should be 
made, depending on the extent of their risks they should receive more intensive surveillance or 
genetic counseling.
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Samenvatting;
Hoofdstuk 1;
In hoofdstuk 1 wordt een introductie gegeven over het bevolkingsonderzoek naar borstkanker. 
Verschillende aspecten van het bevolkingsonderzoek naar borstkanker worden besproken, zoals 
onder meer;
• Epidemiologie van borstkanker
• Primaire en secundaire preventie
• Bevolkingsonderzoek bij jongere vrouwen
• Bevolkingsonderzoek bij oudere vrouwen
• Interval tussen screeningsrondes
• Diagnostische procedure
• Naaldbiopten
• MRI van de borst
• Therapeutische procedure
• Fout-positieve resultaten
• Intervalcarcinomen
• Minimaal invasieve chirurgische behandeling van borstkanker 
Hoofdstuk 2;
Hoofdstuk 2 geeft een overzicht van de doelstellingen van de verschillende studies die in dit 
proefschrift worden besproken.
Hoofdstuk 3;
We weten dat het bevolkingsonderzoek naar borstkanker ertoe heeft geleid dat tumoren in een 
vroeger stadium worden gediagnostiseerd, waardoor ze ten tijde van detectie kleiner zijn en er 
minder vaak uitzaaiingen in de lymfeklieren voorkomen. We vroegen ons af of de daling in de 
mortaliteit die optreedt na invoering van het bevolkingsonderzoek te wijten is aan detectie in een 
eerder stadium of aan een andere tumorbiologie, zich uitend in een lagere Mitotische Activiteits 
Index (MAI). Daarnaast vroegen we ons af of in ons materiaal de MAI een prognostische factor 
is voor ziektevrije overleving.
Er werd een retrospectieve studie uitgevoerd bij 387 patiënten met borstkanker die werden 
behandeld in het UMCN te Nijmegen tussen januari 1992 en september 1997. Bij 90 patiënten 
werd borstkanker ontdekt door het bevolkingsonderzoek, bij 297 werd borstkanker vastgesteld 
buiten het bevolkingsonderzoek om. De MAI en andere prognostische factoren en de ziektevrije 
overleving werden bepaald bij alle patiënten.
De MAI bij de tumoren die niet via het bevolkingsonderzoek werden ontdekt was tweemaal zo 
hoog als bij tumoren die wel via het bevolkingsonderzoek werden ontdekt, zelfs nadat correctie 
voor het stadium van de ziekte werd uitgevoerd. De MAI correleerde goed met andere
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prognostische factoren en bleek in een multivariate analyse een onafhankelijke prognostische 
factor voor ziektevrije overleving.
De betere prognose van patiënten met borstkanker die via het bevolkingsonderzoek werden 
gediagnostiseerd kan inderdaad niet alleen worden verklaard door een eerder stadium van de 
ziekte, maar kan ook worden verklaard door een minder agressief karakter van deze tumoren.
Hoofdstuk 4;
Sinds de invoering van het bevolkingsonderzoek naar borstkanker, zijn er veel tumoren ontdekt 
in de screeningsronden. Echter ook tussen twee screeningsronden door, na een eerder negatief 
resultaat, kan borstkanker worden ontdekt. Deze zogeheten intervalcarcinomen hebben een 
prognose die ligt tussen de prognose van door bevolkingsonderzoek ontdekte carcinomen en de 
prognose van symptomatische carcinomen. Aangezien de Mitotische Activiteits Index (MAI) een 
prognostische factor is voor ziektevrije overleving, hebben we de MAI van de intervalcarcinomen 
vergeleken met die van door bevolkingsonderzoek ontdekte en overige symptomatische tumoren. 
Tussen 1991 en 1999 werd de MAI bepaald in 581 tumoren; 160 (28%) ontdekt in het 
bevolkingsonderzoek, 66 (11%) intervalcarcinomen en 355 (61%) symptomatische carcinomen. 
Naast de MAI werden andere prognostische factoren geregistreerd.
De intervalcarcinomen hadden een significant hogere mediane MAI (17-18, tussen 1-134) dan de 
door het bevolkingsonderzoek ontdekte carcinomen (7-8, tussen 0-94), maar er was geen verschil 
met de symptomatische carcinomen (15, tussen 0-149, p=0.92). Intervalcarcinomen hadden een 
intermediaire uitkomst met betrekking tot andere prognostische factoren, in vergelijking met de 
andere twee groepen.
We konden concluderen dat intervalcarcinomen van de borst een hogere MAI hebben dan 
carcinomen die ontdekt zijn via het bevolkingsonderzoek, hetgeen een agressiever biologisch 
gedrag indiceert. De MAI in de interval groep is echter niet significant hoger dan in de 
symptomatische groep.
Hoofdstuk 5;
Het is de bedoeling van de studie die in hoofdstuk 5 wordt beschreven om na te gaan of patiënten 
met borstkanker, die een positieve familieanamnese voor borstkanker hebben, in een eerder 
stadium worden ontdekt en behandeld. Er werd gekeken naar verschillen in prognostische 
factoren tussen groepen patiënten die wel of geen positieve familieanamnese hebben voor 
borstkanker.
In 481 patiënten werden tumor grootte, tumortype, bloedvatinvasie, receptorstatus, lymfatische 
uitbreiding, MAI en overleving gemeten en vergeleken, waarbij een onderverdeling gemaakt 
werd naar aanleiding van de familieanamnese.
Er werden in deze factoren geen verschillen vastgesteld tussen patiënten zonder positieve 
familieanamnese, patiënten met eerstegraads verwanten met borstkanker of patiënten met 
tweedegraads verwanten met borstkanker. De tumoren werden bij deze patiënten in dezelfde 
stadia ontdekt, met dezelfde prognostische factoren, MAI en overleving.
Het lijkt erop dat ook een positieve familieanamnese op dit moment niet leidt tot detectie van 
borstkanker in een eerder, beter behandelbaar stadium.
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Hoofdstuk 6;
Het bevolkingsonderzoek naar borstkanker leidt theoretisch tot meer diagnostische procedures. 
Het doel van hoofdstuk 6 was om na te gaan welke factoren ertoe leiden dat een lumpectomie als 
eerste behandeling van borstkanker, onvoldoende radicaal wordt uitgevoerd, zich uitend in een 
tumorpositief sneevlak.
Een beschrijvende, prospectieve studie werd uitgevoerd in het IJsselland Ziekenhuis te Capelle 
aan den IJssel; tussen januari 1998 en december 1999 werden 110 vrouwen geïncludeerd met een 
mediane leeftijd van 62 jaar (26-88 jaar). Er werd bekeken welke indicaties werden gesteld voor 
een tweede operatie en de uitslagen van de patholoog werden bestudeerd. De positieve 
sneevlakken, heroperaties en tumorresten in relumpectomie-preparaten werden geregistreerd. 
Diagnostische opzet van de procedure (p=0,015), grotere tumoren (p=0,023), multifocale 
tumoren (p=0,0014), positieve sneevlakken (p<0,05) en tumoren met een uitgebreide in situ 
component (p=0,02) zijn allemaal factoren die bijdragen aan het aantal reexcisies. Resttumor 
werd vaker gevonden bij jongere patiënten (p=0,03), na een diagnostische excisie (p=0,05), 
indien de primaire tumor alleen uit DCIS bestaat (p=0,0085), na een relatief klein excisiebiopt 
(p=0,0051), bij slechtere differentiatie (p=0,033), bij multifocale tumoren (p=0,0026), na een 
positief sneevlak (p=0,011) of als er een uitgebreide in situ component bestaat (p=0,0044).
We hebben geconcludeerd dat er meerdere factoren konden worden geïdentificeerd die bijdragen 
aan het aantal heroperaties en de aanwezigheid van resttumor na een lumpectomie. Het 
ondergaan van een röntgengeleid excisiebiopt behoort niet tot deze factoren.
Hoofdstuk 7;
In deze studie werd de pijnbeleving van vrouwen die deelnemen aan het bevolkingsonderzoek 
naar borstkanker bestudeerd. Mogelijke associaties met de persoonlijke en medische 
voorgeschiedenis, sociodemografische en andere factoren werden bestudeerd. Er werd vooral op 
gelet of de intentie om aan een volgende ronde deel te nemen negatief werd beïnvloed door een 
pijnlijke ervaring.
In Nederland worden vrouwen tussen 50 en 75 jaar tweejaarlijks opgeroepen voor het 
bevolkingsonderzoek naar borstkanker. Aan 1200 deelneemsters werd gevraagd een vragenlijst in 
te vullen.
Het responspercentage was 79,5% (n=954) en 945 vragenlijsten bevatten adequaat materiaal voor 
de analyse. Mammografie werd als matig tot ernstig pijnlijk beoordeeld door 689 vrouwen 
(72,9%). In vergelijking met de groep vrouwen die geen pijn scoorden kwamen de volgende 
omstandigheden significant vaker voor: gevoelige borsten (p=0.001), familieanamnese met 
ziekten van de borst (p=0.017), eerder pijnlijke ervaring door mammografie (p=0.001), hoge 
opleiding (p=0.008), angst (p=0.001), gevoelige borsten tijdens de drie dagen voorafgaande aan 
het onderzoek (p=0.001) en onvoldoende aandacht van de röntgenlaborant (p=0.001). Andere 
factoren zoals leeftijd, hormonale status, grootte van de borsten en hormoongebruik werden niet 
geassocieerd met de pijnbeleving. Tweeëndertig vrouwen (3.3%) gaven aan dat ze niet aan een 
volgende ronde zouden deelnemen: 26 (2.7%) door de pijnklachten, zes (0.6%) om andere 
redenen.
Een zeer groot deel van de vrouwen die aan het bevolkingsonderzoek naar borstkanker 
deelnemen geeft aan dat het onderzoek pijnlijk is (72.9%). De factoren die hierbij een rol spelen 
werden beschreven. Slechts weinig vrouwen (2.7%) geven aan dat ze ten gevolge van deze
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pijnbeleving afzien van verdere onderzoeken. Er worden in het artikel aanbevelingen gedaan om 
de pijn, zoals die wordt ervaren tijdens een mammografie, te reduceren.
Hoofdstuk 8;
In dit hoofdstuk worden de ervaringen met de behandeling van niet palpabele vormen van 
borstkanker bestudeerd.
In een retrospectieve studie werd een groep van 102 patiënten geëvalueerd welke behandeld 
waren tussen 1980 en 1993 in het UMCN te Nijmegen. De meeste tumoren waren ontdekt tijdens 
het bevolkingsonderzoek.
De door de patholoog gemeten diameter was 3 mm (SD 7.7 mm) groter dan de diameter op een 
eerder mammogram (p=0.0029). Bij 77 patiënten (75%) was sprake van een pT1 tumor, bij 17 
(17%) patiënten van een pT2 tumor. Lymfekliermetastasen werden gevonden in 26 patiënten 
(25%), de overigen hadden geen metastasen naar de oksel. Het tumortype was meestal invasief 
ductaal.
Mortaliteit ten gevolge van borstkanker kwam bij twee patiënten voor. De 10-jaars ziektevrije 
overleving bedroeg 94%, nadat vier patiënten die ten tijde van de operatie al bekend waren met 
uitzaaiingen (M1) werden geëxcludeerd. De 10-jaars overleving bij T1a, T1b en T1c bedroeg 
respectievelijk 100%, 96% en 96%.
In de door ons onderzochte populatie is door vroegdetectie en multidisciplinaire behandeling de 
overleving van niet-palpabele mammacarcinomen op een zeer hoog niveau gebracht. De 
toekomstige ontwikkelingen in de behandeling van de groep patiënten met deze tumoren zouden 
gericht moeten zijn op het gebruik van minder invasieve behandelingen, waardoor de morbiditeit 
afneemt, terwijl gelijktijdig het hoge niveau van de overleving gehandhaafd blijft.
Hoofdstuk 9;
Na een fout-positief resultaat van het bevolkingsonderzoek naar borstkanker lopen vrouwen nog 
steeds een risico op het krijgen van borstkanker. In deze studie is de incidentie van borstkanker in 
een groep vrouwen die een fout-positief resultaat had vergeleken met de berekende incidentie in 
een groep controles, die dezelfde patiëntfactoren had.
De gegevens van de follow-up van 188 vrouwen (gemiddelde leeftijd 58 jaar) die een fout- 
positief resultaat hadden werden verzameld en geanalyseerd. De duur van de follow-up was 
gemiddeld 7,4 jaar. Met behulp van gegevens van de locale instantie die de kankerregistratie 
beheert kon de te verwachten incidentie van borstkanker worden berekend en vergeleken worden 
met de verzamelde gegevens.
In de groep vrouwen met een fout positief resultaat in het bevolkingsonderzoek werden zeven 
gevallen van borstkanker vastgesteld, dit is niet significant hoger dan de berekende incidentie 
(n=5) in de controle groep.
Onze conclusie was dat patiënten met fout-positieve resultaten van het bevolkingsonderzoek geen 
hoger risico lopen op het ontwikkelen van borstkanker. Deze groep patiënten behoeft geen 
intensieve controle, maar kan worden terugverwezen naar het bevolkingsonderzoek, tenzij er om 
andere redenen een verhoogd risico bestaat.
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Hoofdstuk 10;
Het bevolkingsonderzoek naar borstkanker heeft onder andere tot gevolg dat veel goedaardige 
afwijkingen worden ontdekt en zelfs operatief worden verwijderd. De follow-up van deze 
aandoeningen in de regio Nijmegen is geïnventariseerd, teneinde een indruk te krijgen over het 
beloop van deze patiënten.
In de twee Nijmeegse ziekenhuizen werden 188 patiënten geïdentificeerd waarbij tijdens het 
bevolkingsonderzoek een afwijkend mammogram was gesignaleerd, maar waarbij bij verdere 
analyse sprake bleek te zijn van een benigne laesie. De gegevens van deze 188 patiënten werden 
verzameld uit de dossiers, daarnaast werd informatie verkregen van de organisatie die het 
bevolkingsonderzoek uitvoert (SVOKON) en van de huisartsen (schriftelijk). Er werd ook 
geregistreerd of deze patiënten borstkanker ontwikkelden.
De follow-up duur in de studie was 7,7 jaar. De gemiddelde poliklinische follow-up van de 
patiënten na de diagnose van een benigne afwijking was 522 dagen (SD 859) met een mediane 
follow-up duur van 150 dagen. Op de sluitingsdatum van het onderzoek, in augustus 1999, 
stonden 113 vrouwen (62%) nog ergens onder controle. De overigen waren ontslagen uit follow- 
up (13 vrouwen) of verloren uit de follow-up (36 vrouwen). Van de 113 vrouwen die 
gecontroleerd werden, werd 78% door het bevolkingsonderzoek gecontroleerd, 12% poliklinisch 
en 10% door de huisarts.
Het viel op dat de instanties niet van elkaar weten wie de patiënten controleert. Hierdoor raakten 
veel patiënten verloren uit follow-up. Logistiek gezien ligt het voor de hand deze patiënten terug 
te sturen naar het bevolkingsonderzoek. In het merendeel van de gevallen is dit al zo.
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Aanbevelingen
Patiënten met borstkanker, welke door middel van het bevolkingsonderzoek werd 
gediagnosticeerd, hebben doorgaans een tumor met een minder agressief biologisch 
gedrag en een betere prognose. Vanuit deze optiek is het verstandig om aan het 
bevolkingsonderzoek deel te nemen.
Intervalcarcinomen zijn niet agressiever dan andere symptomatische vormen van 
borstkanker. De behandeling van intervalcarcinomen kan op de gebruikelijke wijze 
plaatsvinden.
Een belaste familie-anamnese is blijkbaar niet een voldoende grond voor ongerustheid 
bij vrouwen om ervoor te zorgen dat borstkanker in deze groep vrouwen eerder 
geconstateerd wordt. Er moet meer aandacht worden beteed aan risicogroepen om meer 
vroegdetectie te verkrijgen en daardoor de overleving te verbeteren.
Draadgeleide röntgenlokalisatie van moeilijk te palperen of niet-palpabele afwijkingen 
kan veilig gebruikt worden indien er een indicatie voor lumpectomie is gesteld. Het zal 
niet leiden tot een toename van het percentage tumorpositieve sneevlakken.
Pijn bij het maken van een mammografie moet voorkomen worden. Een minder 
pijnlijke ervaring zal ertoe leiden dat meer vrouwen aan een volgende ronde van het 
bevolkingsonderzoek deelnemen. Het geven van informatie en wegnemen van angst 
behoren ook tot de mogelijkheden. Daarnaast bestaan er tegenwoordig methoden 
waarbij de vrouw zelf de druk van het apparaat kan regelen.
Toekomstige ontwikkelingen in de behandeling van borstkanker moeten worden 
gericht op minder invasieve technieken in geselecteerde groepen patiënten. Een 
verdere toename van de toch al zeer hoge overleving in deze groepen lijkt 
onwaarschijnlijk. Het verminderen van de morbiditeit door de behandeling is een 
uitdaging.
Het is veilig om patiënten na een fout-positief resultaat van het bevolkingsonderzoek 
terug te sturen naar de organisatie die het bevolkingsonderzoek uitvoert, onder 
voorwaarde dat een afsluitende mammografie is gemaakt enkele maanden na een 
operatieve procedure. Dit geldt voor zowel geopereerde als niet geopereerde vrouwen. 
Dit lijkt ook een goede strategie om te voorkomen dat huisarts, specialist en organisatie 
van het bevolkingsonderzoek niet weten wie de follow-up eigenlijk uitvoert, waardoor 
een aantal vrouwen niet meer vervolgd wordt. Uiteraard moet een uitzondering 
gemaakt worden voor vrouwen die een verhoogd risico hebben op het ontwikkelen van 
borstkanker. Afhankelijk van de inschatting van dat risico komt deze groep in 
aanmerking voor intensieve surveillance of genetic counseling.
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